CPC preshow newspaper april15 by CloserStill Media

Innovation of the Year Award

Industry Suppliers

Full Conference Programme

SEE PAGE 4

SEE PAGE 10

SEE PAGE 6

www.pharmacycongress.co.uk/facebook

@CPCongress

The Clinical Pharmacy Congress Network

FUTURE-PROOFING CLINICAL PHARMACY Profession gears up for its biggest ever Congress Taking place less than two weeks before the 2015 General Election, this year’s Clinical Pharmacy Congress is perfectly timed to help define the future direction of clinical pharmacy policy and strategy in the NHS. Around 130 professional and commercial bodies have signed up as education and commercial partners to support this year’s Clinical Pharmacy Congress, taking place at London ExCeL on April 24th – 25th. Over the two days of the event, visitors will have the chance to see and hear the very latest in clinical pharmacy thinking as the NHS potentially faces a change of political direction. Over 62 hours of cutting-edge content and over 16 hours’ of exhibition visiting time have been planned in, as well as unprecedented access to the very best in clinical pharmacy strategy and practice. With around 2,000 decision-maker pharmacy delegates expected to attend, there are unrivalled opportunities for valuable networking as well.

A forum for the future of clinical pharmacy Setting out the direction for the overall Congress agenda will be the keynote address from NHS England Deputy Chief Pharmaceutical Officer Dr Bruce Warner. Providing further inspiration for today’s clinical pharmacy professionals will be the winners in this year’s Best of Clinical Pharmacy Awards, which make a welcome return to the Congress after their successful debut last year. A key innovation for this year’s Congress is the Policy and Strategy Forum, where over both days, the UK’s very best thought-leaders in clinical pharmacy will discuss a complete range of key strategic deliverables. Key names in the clinical pharmacy world, including General Pharmaceutical Council Chief Executive and Registrar Duncan Rudkin, and Steve Williams, NHS England’s Senior Head of Safer Medication and Medical Devices are all due to speak. On the agenda are the pressing discussion topics for the modern day NHS such as specialised commissioning, continuous quality improvement, outpatient dispensing, medicines safety and biosimilars. Completing the offer at this year’s Congress is the Innovation & Technology Forum, which will offer visitors much-needed insight into key NHS strategic policy areas such as Summary Care Records in hospital and in community pharmacy,

PRE-CONGRESS NEWSPAPER 2015

SimMan 3G to provide live handson training Over the past two decades, there has been an adoption of simulation in healthcare education internationally. Medical simulation is increasingly becoming established as an important route to safer patient practice and along with technological advances in the development of mobile patient simulators, bringing the benefits of this type of training into many different settings medicine has learned much from professions that have established programs in simulation for training, such as aviation, the military and space exploration. Increased demands on training hours, limited patient encounters, and a focus on patient safety have led to education in healthcare that increasingly involves technology and innovative ways to provide a standardised curriculum. The SimMan 3G is the next generation of Laerdal simulation. SimMan 3G is a ground-breaking simulation solution that can display both physiological and neurological signs and symptoms. Completely wireless and self-contained, technically advanced and yet so easy to use; there is no patient simulator to rival it.

collaborative care to reduce unscheduled hospital attendance and NHS e-procurement strategy. Together the programme will ensure that today’s delegates come away from their Congress experience with the skills they need to meet the strategic challenges of tomorrow.

Instructors can now take advantage of pre-programmed pharmacological responses for over 149 drugs and devices, repeatedly run the most complex cases with ease and adapt difficulties to challenge the skills of every student. The advanced Drug Recognition System allows students to administer drugs simultaneously. It registers the amount, speed and type of drug automatically and applies the appropriate physiological responses, saving the instructor time and improving the overall intelligent debrief.

Seven theatre programmes In total seven stimulating conference theatre programmes have been planned, each delivering a valuable combination of practical learning skills, thought-leadership and inspiration for clinical excellence. The Congress theatre programmes also cover strategic areas such as leadership, clinical practice and medicines optimisation skills. Keynote and leadership programmes: With the general election just around the corner, clinical pharmacy professionals are rightly considering how to future-proof their profession. Whatever the Election outcome, NHS austerity measures will not go away any time soon and Keynote and Leadership sessions such as Pharmacists and GP surgeries (Keynote theatre, Friday 2:15pm) and Leadership in Practice (Leadership theatre, Saturday 3:15pm) are well timed to help clinical pharmacists improve care and boost much-needed efficiencies, at the same CONT. P3 time as reducing costs.

Congress offers hands on experience with the SimMan 3G during scenario sessions run by run by the SimMan faculty. Come along and see how using a patient simulator can enhance theory based teaching and how it can allow you to develop skills in a safe environment.

CIETY SO

ROYAL P H

EU MAC TICA AR

Accredited by:

Conference partners:

Leadership partner:

E DIT E D

5 201

Strategy and Policy Forum sponsor: PE

Charity partner:

Education partners:

UK Renal Pharmacy Group

www.pharmacycongress.co.uk

! W NE

Congress Poster Zone – sharing best practice Don’t miss out on our fantastic NEW Poster Zone at this year’s Congress! Over 100 abstracts were submitted and reviewed by our independent panel, and 80 were selected to be on show over the two days. The Poster Zone will be located on the exhibition floor and will display posters over four different sessions, submitted by pharmacy professionals from NHS Trusts, private health care, prisons, and care homes, as follows: They will showcase work, both completed and on-going.

Session A: Friday

9:30 – 11:00

Session B: Friday

14:30 – 16:00

Session C: Saturday

9:45 – 11:15

Session D: Saturday

14:00 – 15:30

Each Poster will be displayed for 90 minutes on either Friday or Saturday meaning no one will miss out on all the other opportunities available. Presenters have been asked to be present for the duration of the session they are selected for. Please do make sure you visit this area and ask some interesting questions. All the abstracts can be found online please feel free to download the PDFs to your smart phones or tablets we are trying to save on paper. There will be limited copies available onsite should you require one.

The Poster Zone is kindly sponsored by:

Our 2015 Clinical Pharmacy Congress education partners

Our extensive and comprehensive programme of speciality education is what makes the Clinical Pharmacy Congress such a special date in the clinical pharmacy calendar. We are delighted to introduce the following specialist organisations as our 2015 Clinical Pharmacy Congress Education partners:

POSTCARD COMPETITION! Collect a postcard in the registration area upon entering The Clinical Pharmacy Congress to be in with a chance of winning a fantastic prize. Visit the named exhibitors at The Congress and answer a short question about their products and services getting your postcard stamped as verification. Once completed, all correctly answered cards will be entered into a prize draw to win a Weekend Break for two in Paris. (terms and conditions apply). The lucky winner last year was Deborah Gouveia, a Hospital Pharmacist from The Royal Marsden NHS Foundation Trust. Below she tells us her experience at The Congress “We would like to thank the teams at the Clinical Pharmacy Congress and CloserStill Media for arranging our luxury weekend away for two in Paris via the Eurostar. Imagine my surprise when I received a telephone call after having attended the full weekend conference informing me that I had actually won the ‘postcard competition’ which I had entered! I never thought it would be me!! Immediately on arrival at CPC I liked the idea of the postcard competition. It asked that I visit six exhibiting stands and liaise with the stall holders regarding their products. I found it a fun and interactive way to help structure and break the ice when visiting stands amongst the vast number of exhibitors…”

UK Renal Pharmacy Group

VISIT US ON STAND C12

VISIT US ON STAND D18

VISIT US ON STAND C30

VISIT US ON STAND A22

VISIT US ON STAND E35

VISIT US ON STAND G25

VISIT US ON STAND G60

JOIN THE CONVERSATION @CPCongress #CPC15

www.pharmacycongress.co.uk

Congress returns with exciting new features

The Clinical Pharmacy Congress is organised by CloserStill Media Healthcare Limited George House, Coventry Business Park, Herald Avenue, Coventry CV5 6UB. Tel: 02476 717151

Continued from page 1

www.pharmacycongress.co.uk

Clinical: Clinical Pharmacy Congress wouldn’t be complete without a comprehensive programme of clinical education; it’s what makes the Congress such a special date in the pharmacy calendar. This year specialist organisations including UK Clinical Pharmacy Association (UKCPA) and the British Oncology Pharmacy Association (BOPA) will share their insight and expertise in areas including cardiology, asthma, MS and oncology. Intermediate and advanced level sessions designed to share the very latest in clinical thinking are dove-tailed to fit with clinical topics meriting a more strategic discussion. Among these are the sessions on ‘Pharmaceutical care across primary, secondary and tertiary sectors’ (Clinical Theatre 1, Friday 4.30pm) and ‘Unlicensed Medicines: How can patient safety be improved?’ And, if hands-on skills and training are what you are after, why not finish off your clinical experience with a try on the NEW ground-breaking Laerdal Simulation Zone, where you can benefit from simulation training with SimMan 3G? New for this year, is the Poster Zone. Introduced following visitors feedback in previous years, the Poster Zone is your chance for you and your team to learn from fellow professionals’ accomplishments and see the work gain the peer exposure it deserves. For more information on the Poster Zone, visit the dedicated Clinical Pharmacy Congress website area: www.pharmacycongress.co.uk/poster-zone for over 80 entries that will be displayed over the two days. Also well worth a visit is the Congress Education Hub near the entrance of the Show, where visitors can learn from Universities and Colleges about postgraduate education opportunities from across the globe. Medicines Optimisation: Adding strategic direction to clinical programme, the Medicines Optimisation Theatre Programme kicks off with a bar-raising session on ‘Polypharmacy in care homes’ (Medicines Optimisation Theatre, Friday 10.15am).

Laura Shapiro, Senior Congress Manager 02476 719 681, l.shapiro@closerstillmedia.com Matthew Butler, Congress Director 0207 348 5266, m.butler@closerstillmedia.com Lucy Pitt, Marketing Director 02476 719 690, l.pitt@closerstillmedia.com Mihir Patel, Marketing Manager 0207 013 4976, m.patel@closerstillmedia.com

Exhibition Area Of course, the CPD-accredited education programme is just one reason why pharmacy delegates will attend. The Congress also comprises a world-class exhibition, featuring over 130 specialist suppliers of medicines and pharmacy technology and equipment all under one roof. Among the names already signed up to exhibit at this year’s show are: Abloy UK, Actavis UK, ARX, ID Medical, Internis Pharma, Mediwell Systems, Nisus Medical, Pharmacist Support, PharmaPod, Phoenix, Promatica, Stockport Pharmaceuticals and Toshiba Tec.

George Ives, Marketing Executive 0207 348 5256, g.ives@closerstillmedia.com Louise O’Connell, Senior Operations Manager 0207 348 5864, l.oconnell@closerstillmedia.com Rebecca Royal, Operations Executive 0207 348 5277, r.royal@closerstillmedia.com

Don’t miss out!

Kate Jackson, Head of Conferences 0207 348 5754, kate.jackson@closerstillmedia.com

Pressure on budgets makes it harder than ever for suppliers and service providers to come together to reflect, plan, act and evaluate how best to improve pharmacy services for the benefit of patients. Out there – on the front line of NHS care pharmacy professionals may feel they are on their own. But this year’s Clinical Pharmacy Congress is their opportunity to meet, network, and share the expertise and insight of pharmacy’s leading players – and all under one roof. If you don’t want to miss out on this once-a-year event – register now - by visiting: www.pharmacycongress.co.uk or Mihir Patel on 0207 013 4976 or m.patel@closerstillmedia.com

Show information and timings Friday 24th April: 08:30 – 18:15 (Hall S1) (networking drinks from 18:15 – 19:30) Saturday 25th April: 08:30 – 16:15 (Hall S1)

Travel

n C ontribute to your Continuing Professional Development (CPD) n S upport you with your wider professional development, including professional development as part of your RPS Faculty portfolio n C ontribute to supporting you with delivering excellent pharmacy practice and patient care

Rail & Tube

EU MAC TICA R A

CIETY SO

RPS accreditation ensures that you can be assured that the sessions and presentations at this conference will:

The Clinical Pharmacy Congress is held at the ExCeL London ( Halls S1-4 ), which is located 10 minutes from Canary Wharf, in the heart of London’s Royal Docks. There is easy access to the venue via road, rail and air.

RPS accreditation involves a rigorous process of quality assurance against agreed RPS accreditation standards. By successfully achieving RPS accreditation the organisers of CPC have demonstrated the event meets recognised RPS standards for quality and content.

ROYAL P H

The Clinical Pharmacy Congress is RPS Accredited CloserStill Media and the Royal Pharmaceutical Society (RPS) are delighted to confirm that, for the second consecutive year, the Clinical Pharmacy Congress (CPC) 2015 has been accredited by the RPS. Accreditation with the RPS means that the event complies with the RPS Accreditation Standards and Criteria for quality and content and that participation, together with effective evaluation, will enable visitors to gain skills, knowledge and attributes for their professional development.

1 E DIT E D 20

The Royal Pharmaceutical Society is the dedicated professional body for pharmacists in England, Scotland and Wales. Clinical Pharmacy Congress Manager Laura Shapiro said: “We are delighted to receive accreditation by the RPS. The RPS has positioned itself as the place for pharmacists to go to advance their professional practice. These aims resonate exactly with the objectives of the Clinical Pharmacy Congress, and we look forward to helping pharmacists exceed their aspirations and ambitions for clinical practice development again at the 2015 show.”

The Jubilee Line is recommended as the quickest route towards ExCeL and ICC London from Central London. Alight at Canning Town to change onto the Docklands Light Railway (DLR) bound for Beckton, getting off at Custom House. (use stairs, escalators or lift up to the DLR platform). DLR trains toward the venue normally depart from platform 3. ExCeL London and ICC London are located in zone 3. London Underground tickets are valid on the DLR.

Road When driving to ExCeL London follow signs for Royal Docks, City Airport and ExCeL. There is easy access from the M25, M11, A406 and A13. For Sat Nav purposes, we recommend using postcode - E16 1DR. ExCeL London offers on-site car parking for 3,700 cars.

Air ExCeL London is easy to get to from London’s five main airports - London City, Heathrow, Gatwick, Stansted and Luton - via Docklands Light Railway (DLR), underground and mainline rail services.

For further information, please visit the London ExCeL travel page.

www.pharmacycongress.co.uk

Innovation of the Year Award The following abstracts are for the four shortlisted candidates for the Innovation of the Year award at the 2015 Clinical Pharmacy Congress. Join them in the Innovation & Technology Forum on Friday 24th at 9:45am when they will look to impress the judges to see who will take home the ultimate prize...

Establishing a programme of medicines optimisation support in care homes Harris, R., Morgan, R., Harling, A.Community Services Medicines Optimisation Team Central Manchester University Hospital NHS Foundation Trust, Manchester. Background Although half a million older people in England1 and a fifth of all United Kingdom residents over 85 years old reside permanently in care homes, lower standard than provided by hospital trusts.2 Care home residents are considered to have complex comorbidities, prescribed around 7-8 medications each.1,3 The potential for polypharmacy3,4 and subsequent risk to patient safety is significant; over 67% of residents will experience at least one medication error.5 Research has shown that robust medication optimisation5 reviews in this patient group (combined with reduced hospital admission rates) can save up to £18,000 per home.2 Objectives • To establish a programme of medicines optimisation in care homes. • To work in collaboration with the multidisciplinary Care Homes Support Team to develop and integrated approach to supporting patients in care homes. • To establish a framework for safe and secure handling of medicines in the care home setting. Method A medicines optimisation review was carried out for each resident, using the GP surgery record and current medications administration record (MAR) charts. Suggested interventions were compiled into letter format and sent to and/or discussed with the resident’s GP for action.

Results

Ethics approval was not required for this project.

Demographics: Total budget for medicines optimisation input to care homes pilot (£):

5000

Total number of medicines optimisations reviews completed:

Nursing patients:

Residential patients:

Mean age (years):

Mean number of repeat medications prescribed per resident: (prior to any interventions being made)

Discussion As can be seen in the above results table (Table 1), the medicines optimisation arm of this locality Care Homes Support project has, so far, contributed considerable improvements to patient safety and care – avoiding 8 likely and 123 possible hospital admissions – whilst also conveying a significant cost saving on the health system as a whole. The demographics of this cohort also reflect those of previous studies, suggesting that our population is similar in its complexity. Should the project be rolled out with further funding, the service will be developed to include additional pharmacist time and potentially a pharmacist independent prescriber.

Clinical Interventions: Total cost savings on drugs prescribed (£): (difference between medications stopped and started, including dispensing fees saved)

14006.95

Total number of device compliance assessments carried out: (e.g. inhaler counselling)

Total numbers of other clinical interventions made: (e.g. patient counselling, ad hoc discussions with GP)

353

References

Patient Safety:

Total number of interventions likely to have prevented hospital admission:

Total number of interventions that may have prevented hospital admission:

123

Total number of governance interventions made: (e.g. staff education, safe handling of medicines practices)

Total number of safety incidents recorded and reported: (via hospital incident reporting system)

Total number of safe handling and storage audits completed:

4. 5.

Table 1: Showing the interim results of the ongoing Care Homes Support project.

Alldred, D. P., Lim, R., Barber, N. et al. Care Homes Use of Medicines Study. The London School of Pharmacy, The University of Surrey and The University of Leeds> Report 2009. Hockey, D. Why Aren’t Care Homes Higher on the Agenda in the Health Debate? Weblog. http://www.kingsfund.org.uk/ blog/2013/10/why-arent-care-homes-higher-agenda-healthdebate [accessed 20/1/2015]. Duerden, M., Avery, T., Payne, R. Polypharmacy and Medicines Optimisation: Making it Safe and Sound. The King’s Fund. Report 2013. The Model of Care Polypharmacy Working Group. Polypharmacy Guidance: October 2012. NHS Scotland. Report 2012. The Royal Pharmaceutical Society. Medicines Optimisation: Helping Patients to Make the Most of Medicines. The Royal Pharmaceutical Society. Report 2013.

A retrospective evaluation of multidisciplinary review of medication in nursing homes Learmouth M, Baqir W, Barrett S, Hughes J, Desai N, Copeland R, Riddle J, Campbell D, Mackintosh J, Laverty A. Northumbria Healthcare NHS Foundation Trust, North Tyneside, UK Background The Care Homes Use of Medicines Study (CHUMS) study1 and the Making Care Safer2 report highlighted medicines use in care homes as an area of concern: medication errors, excess medicines, lack of reviews and residents involvement. The Shine care home project developed a pragmatic framework for pharmacist-led medication reviews where residents and/or family were involved in decisions about medicines3. Reviews were carried out by clinical pharmacists across 20 care homes working in multidisciplinary teams.3 Objectives Quantify the impact of the Shine intervention on hospital admissions (HA), ‘out of hours’ (OOH) calls and general practitioner (GP) visits.

Method The evaluation was conducted in three general practices and four care homes in the Shine project.3 Null hypothesis: no difference in numbers of HA, OOH calls and GP visits before, and after the Shine intervention. Outcome measures were pre- and post- HA, OOH calls and GP visits. Subjects were sampled from the 422 residents reviewed by the Shine project. Residents included if resident at the care home 12 months prior to, and 12 months after Shine intervention. Statistical analysis: 2-tailed Wilcoxon Signed Rank. Results 157 patients were included in the study. There were 173 HA, 120 OOH calls and 2011 GP visits prior to the Shine intervention and 110 HA, 48 OOH calls and 2064 GP visits post-intervention. For HA and OOH calls, the null hypothesis was rejected; there was a statistically significant reduction in HA (ARR 0.4; p=0.002) and OOH calls (ARR 0.45; p=0.001). There was a non-significant increase in GP visits (p=0.608).

Discussion This study has shown that multidisciplinary review of medication in nursing homes can reduce emergency HA and OOH calls whilst making no difference to GP visits. The Shine model3 has the potential to reduce healthcare costs whilst improving quality for care home residents. References 1.

Barber ND, Alldred DP, Raynor DK, et al. Care homes’ use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older people. Quality and Safety in Health Care 2009;18:341-346.

The Health Foundation and Age UK. Learning report: Making care safer. The Health Foundation 2011:1-24. Available at http://www.health.org.uk/ publications/making-care-safer/ (last accessed 30/01/2015)

Baqir W, Barrett S, Desai N, et al. A clinic-ethical framework for multidisciplinary review of medication in nursing homes. BMJ Qual Improv Report 2014;3: doi:10.1136/bmjquality.u203261.w2538. Available at http://qir.bmj.com/content/3/1/u203261.w2538.short?g=w_qir_recent_ tab (last accessed 30/01/2015)

REACH: preventing medication-related emergency readmissions to hospital Blagburn, J. Newcastle upon Tyne Hospitals NHS Foundation Trust Background Preventing avoidable emergency readmissions is a quality indicator of inpatient safety and good transitions of care. Commissioners withhold reimbursement for a proportion of emergency readmissions. Objectives To determine the effect on emergency readmission rate of implementing ‘pharmaceutical care bundles’ (small, person-centred sets of best practice intended to improve patient outcomes with medication) for medicines known to cause harm or be correlated with emergency admission/ readmission. Method We implemented the care bundles on one randomly selected acute ward in the older people’s medicine speciality for one year from February 2013. There were

five key themes in each care bundle, described below with the acronym REACH. A ward with very similar healthcare resource groups and length of stay was identified as a comparator ward. Our Ethics committee considered this to be service development so their approval was not required. Reconciliation of medicines after admission and by timely, accurate discharge communication about medicine changes to facilitate safe transfer of care. Education about medicines in a person-centred way, helping patients understand the value of their medicines. Assessment of each individual’s need for support with their medicines after discharge. Community pharmacy referral for advanced contract services (New Medicines Service and targeted Medicines Use Review) where patients were eligible and able to access it.

Home follow-up by the hospital pharmacy team (using the advanced contract templates) where patients have medication-related risk factors for hospital readmission but were unable to access community pharmacy advanced services. Results The 30-day emergency readmission rate was significantly lower on the intervention ward (n=418) than the control ward (n=490) during the 12 month REACH intervention period (17% vs 22%, p<0.05, z=2.05, two sample z test for difference in proportions of unrelated samples). The readmission rates for the two wards were not significantly different in the 12 month period before the REACH intervention. Discussion In our sample, provision of person-centred pharmaceutical care significantly reduced emergency hospital readmission rate.

www.pharmacycongress.co.uk

A specialist pharmacy team improving outcomes for patients through an integrated medicines optimisation service Howes K, Lewisham CCG, Lewisham; Lai K & Hoad M, Lewisham & Greenwich NHS Trust, Lewisham Context Evidence indicates between 30-50% of patients do not take their medication as recommended1. Medicines are often unintentionally altered when patients move between care settings as information is not always effectively transferred or communicated2. Objective To support patients identified as having or being at high risk of medicine related problems to enable them to remain independent and in their own home for as long as possible. Method A formal pathway was created for referral of patients with medicines-related problems for assessment, individualised support and follow-up by a specialist pharmacy team; not only across primary and secondary care interfaces but also professional, health and social care boundaries. Results From February to November 2014, a total of 611 interventions were made in the 292 patients (average age 77) who were reviewed and discharged by the service. Table 1 summarises some quantitative outcome measures.

Number (Range where applicable)

As % (n=292)

Estimated Cost Saving (Annual Effect)

Number of A&E attendances avoided (assumption from rating of high or very high risk of admission)

114

39.0%

£13,452

Number of hospital admissions avoided (assumption from conversion rate of A&E attendances to admission)

6.8%

£44,820

Outcome

Number of medicines discontinued

158 (1 – 7)

£18,960

Number of social care visits prevented (where medicines administration would have been required)

93 (1 – 3)

£280,046

Table 1: Outcomes associated with interventions

Of the patients who required follow-up in their own home after hospital admission (48/143), 62.5% had further medicines issues which were identified and resolved, supporting the value of a common team following up patients post discharge.

care professionals across interfaces has improved the quality of information transferred and ensured that an individual’s medicines support needs have been met within their own home.

Conclusion Intervention of the team resulted in better outcomes for patients and significant cost savings. The ability for the team to work collaboratively with health and social

References 2.

Horne R et al; Concordance, adherence and compliance in medicine taking; NCCSDO Report; 2005. Royal Pharmaceutical Society; Keeping patients safe when they transfer between care providers – getting the medicines right: Good practice guidance for healthcare professions; 2011.

Join us in the Keynote Theatre on Friday 24th to discover the winners of the Best of Clinical Pharmacy Awards 2015

We are delighted to announce the shortlisted candidates for the Clinical Pharmacist of the Year award to be: Paul Rafferty

Andrew Murray

Tariq Azamgarhi

Specialist Clinical Pharmacist, Royal Victoria Hospital Belfast Health &Social Care Trust

Advanced Clinical Specialist Pharmacist Cardiology, Antimicrobial pharmacist and Critical Royal Stoke University Hospital (RSUH) University Care pharmacist, Tunbridge Wells Hospitals of North Midlands NHS Trust Hospital at Pembury

Margaret Ruth Hook

Danielle Wigg

Superintendent Pharmacist, Director, Independent Prescriber Banwell Village Pharmacy

High Specialist Pharmacist, (Pre-Operative Assessment and Surgery), North Bristol NHS Trust

POM

Post Graduate Pharmacy Training

The ONLY UK LICENSED Oral Mg Compound for MAGNESIUM 1 DEFICIENCY

New for 2015 is the Education Hub – built in response to your wishes there will be a specific area (near the entrance) on the exhibition floor where you can learn about a variety of different post-graduate training courses from seven leading Universities and Colleges including:

1 On the 7th Nov. 2014 Magnaspartate was issued a product licence (category POM) for the UK and as such Magnaspartate is the

only UK licensed oral magnesium supplementation for treatment and prevention of magnesium deficiency as diagnosed by a doctor. PL 39972/0002 MAH: Kora Corporation Ltd, t/a Kora Healthcare, Swords Business Park, Swords, Co. Dublin, Ireland

£8.95 Box of 10 sachets

MAGUK_021502 Date of Preparation February 2015

www.pharmacycongress.co.uk

KEYNOTE THEATRE

urphy Professor Anna M

Dr Bruce Warner

Sponsored by:

FRIDAY 24TH APRIL

09:00 09:45

SATURDAY 25TH APRIL

Breakfast symposium: A brief history of time – past, present and future of anticoagulation* This session will provide an overview of the developments of anticoagulation from original ‘blood thinners’ through to unfractionated heparin, warfarin, LMWH through to the more recent developments of NOACs, touching on the development of future indications. Sotiris Antoniou FFRPS MRPharmS MSc Dip Mgt IPresc , Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust and Daniel Buck MPharm DipClinPharm Ipresc, Specialist Pharmacist – Anticoagulation, Wrightington, Wigan and Leigh NHS Foundation Trust

10:15 11:00

Anti-microbial Phil Howard BPharm(Hons) DipClinPharm Ind Presc MRPharmS, Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals NHS Trust In association with:

11:30 12:30

New updates in asthma In this session Anna will provide an overview of recent significant clinical research in asthma relevant to pharmacists, an update of any changes to national asthma guidelines and an insight into new and future drugs and devices which will be licensed to manage asthma. Professor Anna Murphy MSc DPharm MRPharms, Consultant Respiratory Pharmacist, Cardio-respiratory Directorate, University Hospitals of Leicester NHS Trust In association with:

Delivered by:

10:15 11:00

Sotiris Antoniou

Sharron Gordon

Helen Williams

Dr David Branford

11:30 12:15

Keynote address followed by The Best of Clinical Pharmacy Awards Dr Bruce Warner BSc MSc DPharm MRPharmS, Deputy Chief Pharmaceutical Officer, NHS England

Practice Pharmacist: implications for future model of general practice The NHS Five Year Forward View puts pharmacists at the heart of its new proposals. The cornerstone of the forward view is the new models of care that has the potential to unlock the current tensions in the systems. This session will aim to share the experiences of a practice based pharmacist’s role, the outcomes achieved and how this model of care can be widely replicated. The session will highlight the variety of tasks that can be undertaken by a practice pharmacist and thereby aid to improve patient outcomes, address workforce crisis in general practice, financial viability and improved access. Dr Rena Amin BPharm MSc IPP MRPharmS, Joint Associate Director of Medicines Management and Clinical Associate, NHS Greenwich CCG and Hartland Way Surgery and Junaid Bajwa MRCGP MRCS MSc, GP, Conway PMS, Greenwich In association with:

12:45 13:30

Lunch symposium: Inertia in diabetes: the role of the Specialist Pharmacist and how will this be supported by the NHS 5 Year Plan* Inertia in diabetes is a major issue: Specialised services need to move into Pharmacist care but the core of the debate will be around where should these services sit? How do we build this service? Professor Cliff Bailey PhD FRCP(Edin) FRCPathLife and Health Sciences, Professor of Clinical Science and Director of Biomedical Sciences Research, Aston University in Birmingham: Phillip Newland – Jones, Advanced Specialist Pharmacist Practitioner in Diabetes and Alison Tennant, CD Accountable Officer, Quality and Safety Pharmacy Services Clinical Lead, NHS England

12:45 13:30

Lunch symposium: Translating clinical evidence to experience in VTE* The session will be delivered through a range of interactive, patient focussed scenarios focussing on the evidence from clinical trials in VTE to improve patient outcomes. A range of aspects will be covered including VTE services, commissioned activity and VTE management in primary care including transfer of care and management of PE. Sharron Gordon, Consultant Pharmacist Anticoagulation - Haemophilia Network, Hampshire Hospitals NHS Trust and Barbara Clark, Lead Clinical Pharmacist, London Bridge Hospital

Delivered by:

14:15 15:00

COPD: Same old, same old? The treatment of COPD is evolving, but are the evidence and practice keeping up? This presentation will highlight common short falls in diagnosis, where management must be improved and gives an over view of how new models of integrated respiratory team working provide smarter COPD care. Grainne d’Ancona GPhC MSc MClinRes IPrescr MFRPSII, Principal Pharmacist (acute medicine) and Clinical Lecturer, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London In association with:

15:30 16:15

14:00 14:45

Specialist commissioning: what you need to know This session will provide delegates with an update and overview of the current commissioning of high cost medicines that are the commissioning responsibility of NHS England Specialised Services. The session will include: • an overview of how medicines are commissioned and the governance process which is used to prioritise medicines • a description of how area teams are working with Trusts to identify high cost medicine budgets • an update on the Medicines Optimisation CRG Malcolm Qualie MSc BSc (Hons) MGPC MRPS, Pharmacy Lead, Specialised Services, NHS England

In association with:

In association with: 15:15 16:00

16:30 17:15

17:30 18:15

Acute coronary syndrome: past, present and future pharmacotherapies The presentation will inform delegates as to the rationale for past and current ACS treatments and will take a look at future developments and treatment strategies that are in the pipeline for the treatment of ACS. The session is aimed at delegates with an interest or those practicing in the field of cardiology with a focus pharmacotherapy relevant to patients undergoing primary angioplasty. Paul Wright MFRPSII MRPharmS MSc Ipresc, Lead Cardiac Pharmacist, The Heart Hospital / UCLH Cardiac Services Pharmacists and GP surgeries The Royal Pharmaceutical Society (RPS) established 5 campaigns for the period 2014/15. The first has successfully promoted the role of pharmacists in urgent and emergency care. This will be followed by campaigns to improve how pharmacists work with General Practitioners, show how pharmacists can better manage long term conditions, ensure that care home residents all receive the benefits of clinical advice from pharmacists to improve their treatment and call for more widespread access for community pharmacists to patients records. This session will identify the progress and opportunities for pharmacists wishing to work as a part of GP surgeries Learning outcomes: By the end of the presentation the attenders will know about the opportunities for pharmacists and pharmacy technicians created by the RPS 5 campaigns. In particular they will hear about the latest breaking news on Pharmacists and GP surgeries Dr David Branford PhD FRPharmS FCMHP, Chairman, English Pharmacy Board, Royal Pharmaceutical Society

Intermediate

Advanced

Free Lunch

Hot Drink and Pastry

Chronic kidney disease and the primary/secondary care interface Medicines management for patients with chronic kidney disease presents is well established in the secondary care setting, with specialist roles being well defined in the literature. However there are significant challenges faced by community pharmacists being able to identify this high risk group of patients in their practice. There are a number of modifiable and non-modifiable risk factors for progressive CKD highlighted in the literature. By increasing pharmacists’ awareness of the modifiable risk factors clinicians are able to implement a medicines management strategy that may enhance care and improve outcomes in this group of patients. This presentation aims to illustrate roles that community pharmacy could play in primary care for the prevention of CKD and highlight issues in the transition of care between primary and secondary sectors. Paul Kendrew MRPharmS MSc, Principal Pharmacist, Pharmacy Department, Hull and East Yorkshire Hospitals NHS Trust UK Renal Pharmacy Group

What’s new in cardiology The presentation will review recently published NICE guidance in cardiology, focusing on implications for pharmacy; and review recently published clinical trial data including: - PARADIGM-HF which investigated LCZ696 (valsartan / sacubitril) in the management of heart failure- X-VERT: rivaroxaban in cardioversion - The IMPROVE-IT study (ezetimibe in acute coronary syndromes) Other emerging therapies expected to hit the market in 2015/2016 and expected to have a significant effect on clinical practice, such as edoxaban, alirocumab, cangrelor, vorapxar, will be highlighted. Helen Williams MRPharmS PGDip(Cardiol) Ipresc, Consultant Pharmacist for Cardiovascular Disease for South London, Hosted by Southwark CCG In association with:

This Congress is supported by educational grants from various companies who have not influenced the meeting content or the choice of speakers however those sessions marked with an asterisk (*) are being delivered with input from the sponsoring company.

www.pharmacycongress.co.uk

CLINICAL THEATRE 1

Chloe Benn

Elizabeth Lamerto

Sponsored by:

Jackie Eastwood

ala Jayaprakash Mak

Robert Duncombe

Suma Surendrana

SATURDAY 25TH APRIL

FRIDAY 24TH APRIL

09:00 09:45

Breakfast symposium: Relapse prevention in schizophrenia and the role of the multidisciplinary treatment team* • Relapse prevention and reduced hospitalisation as the primary goal of the treatment team • Acknowledged lack of patient insight in psychosis • The need for positive and coordinated care • Awareness and discussion of available treatment options and the importance of treatment individualisation for improved therapeutic alliance and patient quality of life Jayaprakash Makala, Consultant Psychiatrist, North Staffordshire NHS Trust

10:15 11:00

New high cost medications within gastroenterology – will we be able to use them? In the current NHS market, and with the increasing number of biological medicines used within gastroenterology, what are these medicines, what is the evidence, how should we be using them, is there any guidance and how do we get them commissioned? Jackie Eastwood BSc (Hons) GPhc, Pharmacy Manager, St Marks Hospital, London North West Healthcare NHS Trust

11:30 12:15

Delivery of healthcare to vulnerable patients The presentation explores the definition of vulnerability and how ‘Safeguarding’ operates in health and social care. The importance of providing person-centred care for vulnerable people is described. Case examples relevant to clinical pharmacy practice illustrate key learning points throughout the presentation. Delegates are also signposted to additional resources for support in their practice. Dr Julia Blagburn BSc(Hons) PgDip DPharm MRPharmS, Senior Lead Clinical Pharmacist for Older People’s Medicine & Community Health, Newcastle upon Tyne Hospitals NHS Foundation Trust

Delivered by:

10:15 11:00

13:00 13:45

Liver disease: old problems – new solutions To review common causes and complications associated with liver disease and new treatment approaches to manage them. Sarah Cripps BPharm MSc MRPharmS (IPresc) FFRPS, Consultant Pharmacist Gastroenterology, Oxford University Hospitals NHS Trust Lunch Symposium: In pursuit of excellence in the prevention of AF-related stroke What is the true price of AF-related stroke?* Trudie Lobban, Chief Executive of the Atrial Fibrillation Association considers the devastating impact on patients and carers of AF-related stroke. She also discusses the barriers that exist to identification, diagnosis and effective anticoagulation and asks where we are one year on from NICE guidance in AF. Trudie Lobban, Chief Executive, Atrial Fibrillation Association What can Pharmacists do to improve patient care? Paul Wright, Lead Cardiac Pharmacist, The Heart Hospital, then examines the role of pharmacy in optimal AF patient care – considering both the importance of medication choice to meet differing patient needs and best practice examples to illustrate how pharmacy is working to improve outcomes in AF. Paul Wright, Lead Cardiac Pharmacist, The Heart Hospital

12:45 13:30

14.0014.45

Delivered by:

14:15 15:00

In association with:

15:30 16:15

In association with:

16:30 17:15

17:30 18:15

UK Renal Pharmacy Group

Pharmaceutical care across primary, secondary and tertiary environments The optimisation of treatment is an essential element of patient care and a mechanism to support better outcomes. At the heart of the NHS is the individual patient and the registered list. From this patients pass through other services that should be seamless in their delivery of care. Mark Robinson BPharm MSc MPS GPhC, Medicines, Pharmacy and Medicines Optimisation Advisor, NHS Alliance Pharmacological management of violent and aggressive behaviour in non-mental health settings Patients can present in a range of aggressive and even violent states in many health settings, for a wide variety of reasons. At times it is necessary and appropriate to use medicines to assist in the safe management of the situation. This session will review the medicines that can be used to calm aggressive patients, and consider when these are best used, and how, and the risks associated in doing so. Caroline Parker FRPharmS FCMHP, Consultant Pharmacist Adult Mental Health & Independent Prescriber, Central & North West London NHS Foundation Trust In association with:

Delivered by:

Commissioning of chemotherapy and the impact of changes to the CDF In October 2014 the CDF revised its Standard Operating Procedures so that it was able to change its method of operating. In January 2015 the latest CDF list was released and this included the details of a number of drugs which from March 2015 will no longer be available for new patients. This talk will review the changes made to the CDF and start to examine how treatment pathways are likely to change as a result of these drugs no longer being available. The presentation will also examine the likely impact this will have on pharmacy services. Robert Duncombe MSc BPharm MRPharmS, Director of Pharmacy, The Christie NHS Foundation Trust In association with:

Gastro-oesophageal reflux disease management in children An update on GORD in infants and children based on the NICE guidance published in January 2015. Case studies from practice will be used to illustrate some of the complexities and controversies in management; including use of prokinetics, choice of PPI formulations and the role of hydrolysed infant milks. Chloe Benn MSc MFRPSII MRPharmS, Principal Pharmacist - Women’s and Children’s Services, Royal Free London NHS Foundation Trust

Glomerulonephritis and the nephrotic syndrome The presentation will give an overview of nephrotic syndrome from causes and how patients present, to the treatment options. General management principles for patients with nephrotic syndrome from management of oedema and hypertension to prevention of thromboembolism and introduction of and management of immunosuppression. The main focus will be on treatment strategies for Membranous nephropathy, Minimal change disease, Frequently relapsing steroid sensitive disease, Steroid resistant nephrotic syndrome, FSGS. Finally what does the future hold and what novel therapies are on the horizon for membranous nephropathy. Elizabeth Lamerton BSc (hons) Pharmacy DipClinPharm Independent Prescriber MRPharmS, Principal Clinical Pharmacist / Renal Pharmacist, Salford Royal Hospital NHS Foundation Trust

Lunch symposium: Improving treatment outcomes in type 2 diabetes: SGLT2 inhibitors and INVOKANA*

15:15 16:00

Parkinson’s: taking control For most people living with Parkinson’s, medication is the primary means by which they have control over their symptoms and so control over their lives. However pharmacists have the skills and expertise to play a larger role in the management of people with Parkinson’s and ensuring they have more effective control over their health and wellbeing. In this session, how pharmacists can support people affected by Parkinson’s will be explored with discussions on developments on treatment options, how pharmacists can facilitate people to take control and what Parkinson’s UK are doing to enable professionals, including pharmacists, to play their part in transforming services for everyone. Suma Surendranath, Professional Engagement and Education Manager, Parkinson’s UK and Olivia Moswela BPharm (Hons) MSc (Clinical Pharmacy) MFRPSII, Lead Directorate Specialist Pharmacist for Neurosciences, Oxford University Hospitals NHS Trust In association with:

www.pharmacycongress.co.uk

CLINICAL THEATRE 2

Alison Beaney

Alia Gilani

Sponsored by:

Claire Vaughan

FRIDAY 24TH APRIL

09:00 09:45

Breakfast symposium: Health economics and diabetes: the pound vs. the patient* The aim of this training is to equip healthcare professionals with an understanding of the clinical and economic value of treating diabetes from both patient and provider perspectives. Focus will be on ‘drivers’ of value in the allocation of scarce healthcare resources within the NHS based on principles of evidence-based medicine, efficiency and fairness. Professor Phil McEwan PhD, Professor & Technical Director, Centre for Health Economics, Swansea University

Stroke – your starter for ten This interactive presentation will examine the key role of pharmacists in the care of patients with stroke and look at recent updates in stroke medicine. It will also attempt to shine a light on some “grey areas” of medicines use in stroke, and explore areas of drug treatment for stroke patients that could be further developed or improved. Ian Rowlands MRPharmS IPresc PGDip Clin Pharm MSc APP, Highly Specialist Pharmacist Critical Care, Barts Health NHS Trust

09:00 09:45

10:15 11:00

11:30 12:15 Insight into Actinic Keratosis Management and potential medicines optimisation opportunities* Insight into the management of actinic keratosis in primary care in the Greater Manchester area Due to the wide variation in AK presentations, the range of therapies available, high rates of recurrence and feedback from patients seen in the specialist referral centre, there is a need to gain a deeper understanding of the patient journey from symptoms, through diagnosis and treatment, to outcomes. The project focus was on patients who received topical treatment for AK within the last 5 years, as some of these patients would be amongst the least likely to be referred for specialist AK treatment. The presentation will examine the results of this retrospective audit. Dr John Lear, Consultant Dermatologist, Manchester Royal Infirmary 13:00 13:45

16:3017:15

Lunch symposium: Access to medicines in rheumatology: assessing and presenting the evidence* This symposium will seek to assist pharmacists in product formulary submissions, ensuring patients have access to the most appropriate treatments in line with evidence-based medicine and personalised care. Dr Anthony Grosso will first offer practical advice on how to be successful in submitting formulary applications for Payment by Results (PbR) excluded drugs. Dr Andrew Östör will then provide an overview and assessment of the clinical evidence for the use of biologic monotherapies in RA, incorporating personal clinical experiences throughout. The mode of action of different biologics will be discussed, suggesting why differences in treatment response can be seen. Dr Anthony Grosso, Principal Pharmacist, University College London Hospital and Dr Andrew Östör, Consultant Rheumatologist, Addenbrooke’s Hospital Delivered by:

Rheumatology Andrew Pothecary MSc MRPharmS, Specialist Pharmacist, Rheumatology & Biologics, Royal Cornwall Hospitals NHS Trust

Cancer immunotherapy – concepts and the emerging role The interaction between the immune system and cancer cells has long been recognised. Cancer immunotherapy refers to treatments that can enable a patients’ own immune system to fight their cancer. The presentation will give an overview of the mechanisms that are now being targeted and demonstrating success in cancer research. Pinkie Chambers, Senior Pharmacist Cancer Services, UCLH and Lead Pharmacist, London Cancer

What is the special clinical need for an unlicensed medicine? How can patient safety be improved? The presentation will explore the decision-making process for use of an unlicensed medicine and will explain what is meant by ‘special clinical need’, giving practical examples, and setting this in an up-to-date legal context. It will include the key principles to consider when identifying special clinical need and advising prescribers on evaluation of options for treatment. The potential quality and safety risks of unlicensed medicines will be explained. Alison Beaney DProfFRPharmS, Regional Quality Assurance Specialist Pharmacist, Royal Victoria Infirmary Newcastle upon Tyne In association with:

Delivered by:

15:30 16:15

Women’s health: surgical issues and pregnancy Jane Bass MSc MRPharmS, Senior Pharmacist, women’s services, Guy’s and St Thomas’ NHS Hospital Foundation Trust In association with:

Delivered by:

Medicines optimisation opportunities in actinic keratosis The management of actinic keratosis presents several opportunities to focus on medicines optimisation to improve outcomes and reduce harms to patients. This presentation will explore some of the common issues raised with the medicines optimisation team. Claire Vaughan, Head of Medicines Management, Salford CCG

Breakfast symposium: Tackling the barriers to diabetes management* A session exploring the challenges of clinical inertia and poor concordance in patients with type 2 diabetes with an extended discussion on resources, tools and pharmacotherapy to support the health care professional Alia Gilani, Health Inequalities Pharmacist, NHS Glasgow and Dr David McGrane, Consultant Physician, Southern General Hospital in Glasgow Delivered by:

Lunch symposium: Oncology*

12:45 13:30

14:15 15:00

Tejas Khatau

SATURDAY 25TH APRIL

Delivered by:

10:15 11:00

Phil McEwan

Ian Rowlands

14:00 14:45

Management of the HIV patient for non-specialists There will be an update on the current situation in the UK; the national treatment guidelines and commonly used HIV drug treatments. Key points for pharmacists to note when managing patients living with HIV in the outpatient / primary care and the inpatient settings will be discussed. Sonali Sonecha MrPharmS DipClinPharm, Lead Pharmacist Clinical Commissioning (NHSE) & HIV, HIV Pharmacy Association / Chelsea and Westminster Healthcare NHS Foundation Trust In association with:

Sponsored by:

In association with:

17:30 18:15

Multiple sclerosis: DMTs what are they? An overview of the new disease modifying treatments and when they can be used. Joela Mathews MPharm MRPharmS MFRPSII, Highly Specialist Pharmacist: Neurosciences, Barts and The London NHS Trust

15:15 16:00

Management of ADHD in children and adolescents ADHD is a complex and multi-factorial condition that can affect between 3-7% of school age children. ADHD impacts on a number of domains such as academic progress, mental and emotional health, friendship and relationships. Early identification and management can make a massive difference to the life of patient and their family. Tejas Khatau, Lead Pharmacist – FYPC Division, Leicester Partnership NHS Trust

In association with:

Advanced

Free Lunch

Hot Drink and Pastry

www.pharmacycongress.co.uk

MEDICINES OPTIMISATION WORKSHOPS

Eisha Gosrani

er-Williams Hamish McAllist

FRIDAY 24TH APRIL

10:15 11:00

12:45 13:30

Sponsored by:

Steve McGlynn

Roger Knaggs

Liz Miller

Tahmina Rokib

SATURDAY 25TH APRIL

Polypharmacy in care homes The session aims to address the challenges faced with Polypharmacy within a care home setting by: 1. Learning through case-based scenario discussions 2. Sharing learning from the ‘Proactive Care Homes Project’ at CLCH NHS Trust. Nicole Le Morgan MRPharmS Dip Clin Pharm, Proactive Care Home Medication Review Pharmacist - Medicines Management Team, Central London Community Healthcare NHS Trust and Jenny Butterfield MRPharmS Clin Dip, Community Health Services Pharmacist, Central London Community Healthcare NHS Trust

Lunch symposium: Translating clinical evidence to experience – cardiology* The session will be delivered through a range of interactive, patient centred scenarios focussing on the evidence from clinical trials in cardiology to improve patient outcomes. A range of aspects will be covered including atrial fibrillation and acute coronary syndromes highlighting key challenges in delivering effective anticoagulation. Sotiris Antoniou FFRPS MRPharmS MSc Dip Mgt Ipresc, Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust and Helen Williams MRPharmS PGDip(Cardiol) Ipresc, Consultant Pharmacist for Cardiovascular Disease for South London, Hosted by Southwark CCG

10:15 11:00

11:30 12:15

Clinical case: Fingers on the pulse in AF - rate or rhythm control? Patients presenting with recent onset or poorly rate-controlled atrial fibrillation can be either relatively asymptomatic or may have potentially life threatening symptoms due to acute heart failure or ischaemic stroke. Haemodynamically compromised patients often require rapid rate control via cardioversion to sinus rhythm but this may not be possible if the AF history or its management is unclear. Pharmacological options will depend on clinical status and type of AF. Long-term management usually consists of drug therapy, but may include cardioversion or electrophysiological intervention. Steve McGlynn MSc MRPharmS, Specialist Principal Pharmacist (Cardiology), NHS Greater Glasgow and Clyde

Clinical case: Management of treatment resistant depression There is an extremely strong evidence base demonstrating the efficacy of antidepressants both acutely and prophylactically for the treatment of depression. However, while this is the case, many patients fail to respond adequately to first line treatment. This presentation will consider a) the nature of the data available to guide treatment of refractory depression; b) the evidence base itself and c) will contextualise pharmacotherapy in the management of patients. Dr Hamish McAllister-Williams MD PhD FRCPsych, Reader in Clinical Psychopharmacology, Newcastle University and Northumberland Tyne and Wear NHS Foundation Trust In association with:

Delivered by:

14:15 15:00

Clinical case: Palliative care – one chance to get it right At some stage we are all called to support people towards the end of life whether it’s patients, clients or our family and friends. As patients deteriorate there can be difficult choices to make to preserve quality of life, manage symptoms and pill burden especially when fatigued. This interactive workshop will use clinical cases to discuss recent updates and dilemmas in pharmacological treatment of patients towards the end of life to support you in optimising treatments. We will consider the use of: • NOACs vs LMWH • Oral antidiabetics and insulin • Fast acting fentanyls vs immediate release morphine • Methadone vs Ketamine • And consider de-escalation of medicines in oncology and frail elderly with limited life expectancy. There may well be some time to consider some ethical issues and unlicensed use of medicines as well! Liz Miller BPharm DipPharmPract MRPharmS, Advanced Clinical Pharmacist – Palliative Care, Palliative Care Pharmacists Network

14:00 14:45

In association with:

15:30 16:15

Responsible respiratory prescribing* Responsible Respiratory Prescribing is “Doing the Right Thing and Doing the Right Things Right”. This session will debate the background behind the “guidelines”, reveal the truth that is value based healthcare in respiratory medicine and shock you with how far from this we really are. If you look after anyone with a lung disease, or you have ever added the prefix “only-” or “just-” to asthma or COPD, this session is for you... Grainne d’Ancona GPhC MSc MClinRes IPrescr MFRPSII, Principal Pharmacist (acute medicine) and Clinical Lecturer, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London and Dr Vince Mak, Consultant Physician in Respiratory Integrated Care, Imperial College Healthcare and Central London Community Healthcare NHS Trusts Delivered by:

16:30 17:15

17:30 18:15

Clinical case: Osteoporosis An overview of the risk assessment and management of patients with osteoporosis including recent developments in treatment options. Tahmina Rokib MPharm PGDip, Senior Lecturer – Academic Pharmacist Practitioner, University of Sunderland

Clinical case: Heart failure in acute and chronic cases Life as a cardiovascular specialist in a tertiary referral centre – dealing with a clinical miscellany of simple to the more complex treatments for heart failure. Imran Hafiz MPharm PGDip IP, Principal Cardiovascular Pharmacist, Guy’s and St Thomas’ Hospital and Duncan McRobbie MSc FRPharmS, Associate Chief Pharmacist - Clinical Services, Guy’s and St Thomas’ Hospital In association with:

Clinical case: Epilepsy In this presentation Eisha will look at some of the key issues surrounding the management of anti-epileptic drugs in epilepsy. She will use anonymised case studies from her practice at Epilepsy Society to illustrate these issues, including the potential impact of anti-epileptic medication on pregnancy, the importance of side effects and interactions, the value of therapeutic drug monitoring in epilepsy management, and how medicines optimisation is helping people with epilepsy to self-manage their condition. Eisha’s presentation will facilitate involvement and discussion to improve practice. Eisha Gosrani MRPharmS, Principal Pharmacist , Epilepsy Society

15:15 16:00

Clinical cases: Exploring the correct place for the medicines in pain management Although all types of pain have biological, psychological and social components and influences, treatment strategies and the role of medicines are very different in acute and persistent pains. In this interactive session we will consider the principles of medicines optimisation in acute and persistent pain management. Dr Cathy Stannard FRCA FFPMRCA, Consultant in Pain Medicine, Southmead Hospital, Bristol and Roger Knaggs BSc BMedSci PhD FRPharmS, Associate Professor in Clinical Pharmacy Practice, University of Nottingham & Nottingham University Hospitals NHS Trust

www.pharmacycongress.co.uk

2015 CONGRESS Floor Plan & Ex MEDICINES OPTIMISATION WORKSHOPS

KEYNOTE THEATRE Sponsored by:

Sponsored by:

B60

Special Products

D60

B62 C60 C62

Sintek Bio-Bin Preston Pharmaceuticals

A58

E60

HCA Hospitals

E61

Phoenix

Leo Pharma

E65

Pharmacist Support

Aguettant

A56

B55

Durbin

D50

E55

ITH Pharma

A50 Qdem Pharmaceuticals

C50 Roche Products - Oncology

B50

Bayer Healthcare

E58

F55 Sanofi Diabetes

Sanofi

E53

Denward Manufacturing

F50 F58

E50

Fresenius Kabi

Huddersfield Chiesi Pharmacy Specials

ARX

A45

Shoreline UK

CLINICAL THEATRE 2 Sponsored by:

A44

B40

Nisus Medical

MSD

A30

B45

Mediwell Systems

B48

PharmaNord Specials

Dometic Medical Systems

B30 A28

Spirit Medical

C30 hameln pharmaceuticals

A27

AB Scientific Janssen

Sponsored by:

CAFÉ Sponsored by:

A24

Guy’s Pharmacy Manufacturing Unit

A22

Barts Health NHS Trust

D38

B15

C15

Wockhardt UK

SIMULATION ZONE

A1 CHS

Wiley

Polar B10 Speed Bray Distribution Healthcare

Deep Tissue Massage

SPEAKER & PRESS OFFICE

E42

Kora Healthcare

CPC 2016 Sales Office

E25

Boeringher Ingelheim

Quantum Pharmaceutical D22 / UL Medicines / Biodose DX Group

E20

D16

E15

PCPA

Amdipharm Mercury Company Ltd

D18

D19

E28

Abloy UK AstraZeneca Diabetes

E10 ID Medical

STRATEG POLICY F

Sponsored by:

F35

Thornton& Ross Derma

F31

F38

F30

F39

Epilepsy Society Micronclean AstraZeneca Accord Healthcare

F22 F28 Portsmouth Moorfields P.M.U. Pharmaceuticals

F20

Eastbourne Pharmaceuticals

Seating Area

SoleM

Se Sta

F15 NHS Pharmacy Manufacturing

F10

F18

Labcold Glucomen

Nova Labs

C1Willach Pharmacy Solutions

UPPER MEETING ROOM

D25

PDA

B.Braun Medical

E38 Sanctuary Health

HD Medi

C12

E32 E35

E30

D10

Mylan

D30

Grunenthal Citysprint Healthcare

In partnership with:

B12 B18

E40

IPS Specials

D20

A26

POSTER ZONE

D42 D45 D48

Orion Pharma (UK) Promatica Distinctive Stockport Healthcare Medical Pharmaceuticals Mistura C48 St George’s Teva UK Ltd Grunenthal D40 Ent PMU BD Medical C40 Fagron

C35

Actavis UK

Avantec

C45 C47

ORGANISER’S OFFICE

ENTRANCE

EDUCATION HUB

www.pharmacycongress.co.uk

xhibitor List CLINICAL THEATRE 1 Sponsored by:

G60

H61

Royal Free Specials

Medisca

Torbay Mawdsleys Pharmaceuticals

G50 Daiichi Sankyo

G58

Logixx Pharma

G59

ensible affing

Education Hub

Logixx Pharma

G58

Manchester Pharmacy School

F1A

Mawdsleys

G55

CPD4ALL, Keele University

F1B

Medisca

H61

Bradford College

F1C

Mediwell Systems

B45

Queen’s University Belfast

F1D

Micronclean

F38

Robert Gordon University

F1E

Mistura Ent Ltd

C45

University of Ulster

F1F

Moorfields Pharmaceuticals

F28

Health Education KSS Pharmacy

F1G

MSD

B40

Mylan

C15

H40

Nova Laboratories

D18

H52

Aguettant Ltd

A58

Orion Pharma (UK) Ltd

C47

The London Clinic

Amdipharm Mercury Company Limited

E15

Parkinsons UK

ARX Limited

E50

Pharma Mix

H15

H50

Astra Zeneca Diabetes

E28

Pharma Nord Specials

B48

Astra Zeneca Respiratory

F30

Pharmacist Support

E65

Avantec Healthcare Limited

A28

Pharmacist’s Defence Association

D19

B.Braun Medical

C12

Barts Health NHS Trust

A22

Pharmacy Manufacturing Unit Portsmouth Hospitals NHS Trust

F22

Bayer Healthcare

D50

Pharmacy Medical

H55

BD Medical

D40

PharmaPod

H10

Bio-bin

C60

Phoenix

E61

Biodose

D20

Boehringer Ingelheim

E25

Polar Speed Distribution Ltd

B18

Bray Healthcare

B10

Preston Pharmaceuticals

C62

Bupa Home Healthcare

H42

Promatica Healthcare ltd

D42

Cambridge Healthcare Supplies

Qdem Pharmaceuticals

A50

Chiesi

F50

Quantum Pharmaceutical

D20

RIG Healthcare Recruit

G32

Roche

C50

Rosemont Pharmaceuticals

H19

City Sprint Healthcare

D30

Clinical Pharmacy Congress 2016

E38

CoAcS Ltd

H48

CPPE

H20

Royal Free Specials

G60

Daiichi Sankyo

G50

Royal Pharmaceutical Society

H25

Deep Tissue Massager

Sanctuary Health

E30

Denward Manufacturing Ltd

E52

Sanofi

E58

Distinctive Medical

D45

Sanofi Diabetes

F55

Dometic Medical Systems

A30

Sensible Locums

G21

DURBIN PLC

A56

Shoreline (UK) Ltd

A45

DX Group

D22

Sintek Ltd

B62

Eastbourne Pharmaceuticals

F20

SMPU

F15

Econix Ltd

C60

Sole Mates

G22

Epilepsy Society

F31

Special Products Limited

B60

Fagron

C40

Spirit Medical

C35

Fresenius Kabi Ltd

B50

St George’s NHS Trust

C48

General Pharmaceutical Council

H50

Stockport Pharmaceuticals

D48

GlucoMen

F17

Teva

E40

Grunenthal

E42

Grunenthal

D38

The London Clinic

H52

Guild of Healthcare Pharmacy (GHP)

G28

The Pharmacists’ Defence Association

D19

H10

Guy’s Pharmacy Manufacturing Unit

A24

The Primary Care Pharmacists’ Association

D16

PharmaPod

hameln pharmaceuticals ltd

C30

Thornton & Ross Dermatology

F35

HCA Hospitals

D60

TLTP Medical

G30

HD Medi Ltd

D10

Torbay Pharmaceuticals

G57

Helapet Limited

G25

Toshiba TEC

G1 H26

LEADERSHIP THEATRE

H25 RPS

In partnership with:

H20 CPPE

H15 W = Water Station

PharmaMix

Toshiba iBin Tec Innovations

E60

Added Pharma Ltd

Rosemont Pharmaceuticals

G1 G9

Leo Pharma

F15

H56

H19

UK Renal Pharmacy Group (UKRPG)

North Midlands Pharmacy Specials

H26

Parkinson's UK

G35

B30

UKPCA

INNOVATION & TECHNOLOGY FORUM

F10

Lec Medical

Actavis UK Ltd

G30

GROUP LOUNGE

Labcold

PCCPN

Pharmacy Sanofi Medical Medical

Indivior

G21

NPPG

F15

Internis Pharma

Mates SPECIALIST INTEREST

D25

A44

H29

G22 G20

Kora Healthcare

North Midlands Pharmacy Specials

Added Pharma

GHP

HIV Pharmacy Association (HIVPA)

Nisus Medical Ltd.

G38

Helapet

A26

F39

H42

G28

B55

Janssen

E20

G32

G25

ITH Pharma

College of Mental Health Pharmacy (CMHP)

Accord Healthcare Limited

Lec Medical

TLPT Medical

British Oncology Pharmacy Association (BOPA)

Abloy UK

H40

RIG

E35

F15

Bupa Home Healthcare

G35

IPS Specials

NHS Pharmacy Manufacturing

CoAcS

Association of Pharmacy Technicians UK (APTUK)

A27

H48

GY AND FORUM

Exhibition Hall

GPhC

Written Medicines

Intrapharm Laboratories Ltd

AB Scientific

H55

G55 G57

Specialist Interest Group Lounge – G20

Intrapharm Laboratories

Huddersfield Pharmacy Specials

F58

UKCPA

iBin Innovations

UL Medicines

D20

ID Medical

E10

Wiley

B12

Indivior

H29

Willach Pharmacy Solutions

Internis Pharma

G38

Wockhardt UK Limited

B15

www.pharmacycongress.co.uk

LEADERSHIP THEATRE

Catherine Duggan

Duncan Rudkin

In partnership with:

John Quinn

FRIDAY 24TH APRIL

09:00 09:45

13:00 13:45

Breakfast symposium: Has the classification of drugs for pain been overtaken by successive developments such as Palexia and novel targets? This session presents the case and a solution for a new mechanism-based system. Professor Richard Langford MB;BS FRCA FFPMRCA, Founder/Director of Pain and Anaesthesia Research Centre, Barts Health NHS Trust; Paul Farquhar-Smith, Consultant in Pain and Anaesthetics and Fellow of the Faculty of Pain of the Royal College of Anaesthetists and Anthony Dickenson BSc PhD FmedSci FBPharmcolS, Professor of Neuropharmacology in the Department of Neuroscience, Physiology and Pharmacology, University College, London

The role of professional bodies – workforce development The changing needs and demography of patients and the public has great impact on the development of the pharmacy workforce, creating an imperative to provide support and development, alongside mechanisms to advance and manage complex care and deliver services that meet these changing needs. A flexible workforce needs flexible development and support and we will present how RPS can help. Dr Catherine Duggan PhD FRPharmS, Director of Professional Development and Support, Royal Pharmaceutical Society

Lunch symposium: Pharmacy: pivotal in tackling the emerging trend of opioid analgesic dependency* The level of opioid prescribing has increased over the last 10 years, and there is now a small minority of increasing patient numbers reporting to substance misuse services that have become unintentionally addicted to their opioid painkillers. Pharmacists are well placed to recognise patients who have unintentionally developed addiction to opioid analgesics from POM or OTC medication. This presentation will cover: • What is OAD • How patients become dependent • The current trend for OAD • The role of pharmacy (from prevention, identification, screening to treatment) • My role/experience in OAD • Benefit of pharmacy in helping to tackle OAD Duncan Hill MRPharmS, Specialist Pharmacist in Substance Misuse, NHS Lanarkshire

10:15 11:00

11:30 12:15

14:15 15:00

Urgent and emergency care - do pharmacists have a role? As a profession pharmacists are entering an exciting new era, in which they will have much greater scope to apply their high levels of expertise in direct patient care (Cited in the changing face of pharmacy. RPS). Are we bold enough as a profession to grasp these new opportunities when they present themselves? This presentation will outline one such new opportunity, Pharmacists working in Emergency departments’ not as clinical pharmacists but as Advanced Clinical Practitioners. Professor Anthony Sinclair BSc MSc FRPharmS FFRPS, Director of Pharmacy, Birmingham Children’s Hospital NHS FT

15:30 16:15

Leadership for improvement - how to improve care, improve efficiency and reduce costs We all want to provide the highest quality of care for the patients we serve. Leading quality improvements in healthcare can be challenging, slow, daunting yet exciting. This session will help you understand the leadership behaviours required to improve patient experience and outcomes and reduce cost of care. At the end of the session, you will have a better understanding of approaches you can use and the session will give you some take away tools and techniques to help you design and plan your next improvement intervention. Suzanne Khalid MRPharmS, Associate Director for Quality Improvement and Director of Clinical Support and Imaging Clinical Management Group, University Hospital of Leicester NHS Trust

16:30 17:15

7 day working – the practical implications of delivering 7 day services This presentation provides outlines when and where you should start implementing 7-day services and provides guidance on moving forward. The key to success is the engagement within the department, sharing a common vision, and across the organisation. Use of medicines management pharmacy technicians and pharmacist prescribers can help implementation. Setting key target dates, linked to key corporate requirements and deadlines, will maintain the impetus of the development. Staff should be engaged formally through consultation, and involved via a steering group, with representatives of all ranges of pharmacy staff, to increase ownership and provide innovative ideas for taking forward. Richard Copeland MPhil Ipresc, Head of Clinical Pharmacy/Deputy Chief Pharmacist, Northumbria Healthcare NHS Foundation Trust

17:30 18:15

Foundation and Faculty Beth Ward MFRPSII MRPharmS, Programme Manager; Hannah Wilton MRPharmS, Faculty Development Lead; and Lesley Johnson MRPharmS, Faculty Development Lead, Royal Pharmaceutical Society

Advanced

Free Lunch

Hot Drink and Pastry

Resilience and you This presentation will go through what resilience is and focus on three key areas; personal understanding, resilience in the context of change and stress and resilience in the context of sustaining self over the long term. John Quinn FRPharmS, Divisional Manager, The Heart Hospital / UCLH Cardiac Services Practical updates from the regulator Duncan will provide an overview of some of the key initiatives currently taken forward by the GPhC. These all link in with the wider points around what is expected of the profession to meet future challenges, made in his earlier conference speech on the future of pharmacy. • Expectations in terms of professionalism – Ongoing review of Standards of Conduct, Ethics and Performance • Update on Continuing Fitness to Practise • Future review education and training Standards for pharmacists and pharmacy technicians • Pharmacist prescribing Duncan Rudkin, Chief Executive and Registrar, General Pharmaceutical Council (GPHC) In association with:

12:45 13:30

Lunch symposium: Lipid modification: past, present and future developments* The session will provide an overview of developments in the management of lipids. Describing the role that rabbits played in ‘lipid hypothesis’; to the development of cholesterol lowering agents and beyond statins touching on future developments of managing cholesterol. Sotiris Antoniou FFRPS MRPharmS MSc Dip Mgt IPresc , Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust Delivered by:

14:00 14:45

Using the RPS hospital standards to realise benefits for patients The RPS Standards for Hospital Pharmacy were first introduced in 2012. Since then they have been updated in 2014 following the Francis review. As healthcare evolves we need to continually revisit these standards to ensure we are covering or working towards best practice. This session is aimed at exploring these standards and looking for the practical opportunities they present to enhance the service we provide our patients and/or their carers. Jon Standing BPharm DipClinPharm MRPharmS, Chief Pharmacist, Yeovil District Hospital NHS Foundation Trust

15:15 16:00

Leadership in practice Effective leadership improves patient care and outcomes, as well as staff morale and job satisfaction. Although pharmacists already strongly contribute to the delivery and quality of patient care across all sectors of pharmacy practice, developing leadership behaviours across the profession can enhance this contribution at every level.This presentation will provide the context and background to the new RPS Leadership Development Framework, which aims to encourage engaging leadership development collectively across the profession, irrespective of experience, sector or role. Marianne MacDonald MRPharmS, Leadership Workstream Project Manager, Royal Pharmaceutical Society: Emma Williams MRPharmS (IPresc) PGDip, Principal Pharmacist - Clinical Governance, Guy’s and St.Thomas’ NHS Foundation Trust and Lucy Galloway MFRPSII MRPharmS, Lead Pharmacist Renal, Transplant & Urology, Barts Health NHS Trust Royal London Hospital

Delivered by:

Intermediate

Suzanne Khalid

SATURDAY 25TH APRIL

Delivered by:

10:15 11:00

Richard Copeland

Jon Standing

www.pharmacycongress.co.uk

STRATEGY AND POLICY FORUM

do Diane Ashiru-Ore

Ann Slee

FRIDAY 24TH APRIL

10:00 10:30

Sponsored by:

Sarah Billington

Nicola King

Duncan Rudkin

Steve Williams

SATURDAY 25TH APRIL

The future of pharmacy Observation on the now. What the future might look like know that the way pharmacy services are delivered is changing and evolving at a fast pace. Key questions are asking ourselves are: • What will the role of pharmacists be? • What will the role of pharmacy technicians be? • What services will registered pharmacies provide? This leads on to a discussion: • The expectations on the profession regarding the knowledge, skills, behaviours, leadership and professionalism necessary to meet future challenges. • From a systems perspective, what are the expectations in terms of the standards, culture and accountability required to meet those future challenges. Duncan Rudkin, Chief Executive and Registrar, General Pharmaceutical Council

09:15 09:45

Combating anti-microbial resistance - information for action Antimicrobial resistance (AMR) is a major clinical and public health issue and an important threat to the future of healthcare. All Pharmacists and Pharmacy Teams have a significant role to play in tackling the threat of AMR. This session will provide an update on the national strategies as well as practical examples used by local teams to tackle antimicrobial resistance. Diane Ashiru-Oredope MPharm DipClinPharm MRPharmS, Pharmacist Lead, Public Health England & Department of Health Expert Advisory Committee on AMR & HCAI (ARHAI) In association with:

In association with:

10:45 11:15

Specialised commissioning: national strategy This session will provide delegates with an update and overview of the current commissioning of high cost medicines that are the commissioning responsibility of NHS England Specialised Services. The session will include: • an overview of how medicines are commissioned and the governance process which is used to prioritise medicines. • a description of how area teams are working with Trusts to identify high cost medicine budgets • an update on the Medicines Optimisation CRG Malcolm Qualie MSc BSc (Hons) MGPC MRPS, Pharmacy Lead, Specialised Services, NHS England In association with:

13:00 13:45

Lunch symposium: Moving homecare forward – funding models, partnership working, quality and safety* Bupa Home Healthcare’s pharmacy customers were asked what topics are at the forefront of their minds when thinking about home healthcare overall. Three strong themes came through which will be explored in greater detail during the session: Homecare funding models – what are the options for homecare? Partnership working – how can the NHS, home healthcare providers and the pharmaceutical industry best collaborate and work together? Quality and safety – how are providers working towards safer homecare provision? Stephen Cook, Director of Pharmacy and Quality, Bupa Home Healthcare

10:00 10:30

Medication safety and the role of Medication Safety Officers Steve Williams MPhil BPharm MRPharmS IPresc Clin Dip Pharm, Senior Head of Safer Medication & Medical Devices , NHS England In association with:

11:00 11:30

12:00 12:30

Outpatients dispensing and homecare delivery Arran Thoma, Senior Manager, Indirect Tax, Government & Healthcare UK , KPMG In association with:

Empowering staff to deliver continuous quality improvement as a routine The workshop will discuss how leadership within pharmacy departments and organisations can ensure that continuous quality improvement is a routine part of all staff’s job role. Transformational leadership as a concept to support this will be discussed. Participants will assess how this culture can be initiated and maintained; and which quality improvements tools and techniques can assist. Kevin Gibbs Dip Clin Pharm Cert Health Econ PgC Evidence based Healthcare PgC Law & Ethics, Clinical Pharmacy Manager, University Hospitals Bristol NHSFT

Hosted by Bupa Home Healthcare

14:15 14:45

Care Quality Commission: National update This presentation will inform attendees on the work of CQC of the work of the Medicines Optimisation Team within CQC. This includes • How CQC regulates the safe and effective use of medicines in all care settings • What to expect during a CQC inspection • How judgements are made • How you can contribute to our work Sarah Billington MRPharmS, Head of Medicines Management, Care Quality Commission

14:00 14:30

In association with:

15:00 15:30

ePrescribing - are you delivering your paperless NHS? The presentation will outline the current position as regards the work underway to develop the National Information Board framework and other work relating to ePrescribing in relation to medicines optimisation and the drive towards becoming paperless. Ann Slee, ePrescribing Lead, Strategic Systems and Technology, Patients and Information, NHS England In association with:

15:45 16:15

A strategic update from NHS England Dr Bruce Warner BSc MSc DPharm MRPharmS, Deputy Chief Pharmaceutical Officer, NHS England In association with:

16:30 17:00

2015: The year of the biosimilar Biological and biosimilar medicines have the impact to transform patient outcomes. In the UK, this year is a breakthrough period for biosimilars from a regulatory and patient perspective. The further use of these medicines will save the NHS money which can be used to fund other treatments. Increased biosimilar uptake will also make specific medicines available to patients within the NHS which might otherwise not be approved for use. Warwick Smith, Director General, British Generic Manufacturers Association (BGMA) In association with:

17:15 17:45

Advanced therapy medicinal products – an introduction for pharmacists Advanced Therapy medicinal products include gene, cell and tissue based products. They have often been developed outside of the traditional pharmaceutical arena and are therefore unfamiliar to many pharmacists. Their usage, however, is increasing and pharmacists need to engage in their governance to ensure patient safety. Anne Black BSc (hons) MRPharmS, Assistant Director of Pharmacy – Quality Assurance, The Newcastle upon Tyne Hospitals NHS Foundation Trust

Disclosure of payments to healthcare professionals by the pharmaceutical industry New requirements for pharmaceutical companies to disclose payments they make to individuals came in to effect on 01 Jan this year. If you have worked, or intend to work with a pharmaceutical company this year then payments made to you will be disclosed on a public database during the first half of 2016. Aileen Thompson, Executive Director – Communications for the ABPI and project lead for new requirements, will explain what this means for you. The session will provide a good opportunity for you to ask questions around how the scheme will be delivered. Aileen Thompson, Executive Director – Communications, Association of the British Pharmaceutical Industry (ABPI) In association with:

15:00 15:30

Making sense of the post 2013 NHS commissioning landscape Nicola will explain how the new commissioning system works and which organisations are responsible for what. She will explore how CCGs make decisions and who is really in charge. Finally she will help identify where the future opportunities might be for pharmacy and pharmacists. Learning outcomes: 1. How CCGs work2. Who does what in the new commissioning system 3. Where are the opportunities for pharmacy Nicola M King , Managing Director, thiNKnow limited

www.pharmacycongress.co.uk

INNOVATION & TECHNOLOGY FORUM SATURDAY 25TH APRIL

FRIDAY 24TH APRIL 09:4510.45

11:0011.30

The Best of Clinical Pharmacy Innovation Award Shortlist presentations See Page 4 for more details Disclosure of payments to healthcare professionals by the pharmaceutical industry New requirements for pharmaceutical companies to disclose payments they make to individuals came in to effect on 01 Jan this year. If you have worked, or intend to work with a pharmaceutical company this year then payments made to you will be disclosed on a public database during the first half of 2016. Aileen Thompson, Executive Director – Communications for the ABPI and project lead for new requirements, will explain what this means for you. The session will provide a good opportunity for you to ask questions around how the scheme will be delivered. Aileen Thompson, Executive Director – Communications, Association of the British Pharmaceutical Industry In association with:

14.15 14.45

09:00 09:45

Delivered by:

10:15 10:45

Medicines optimisation in hospital and at the interface through effective commissioning - the role of a Commissioning Pharmacist • Overview of NHS medicines commissioning arrangements and processes in England • Opportunities and barriers to optimise medicines use in hospital and at the interface from a Commissioning Pharmacist’s perspective • How can a Commissioning Pharmacist make a difference?- Practical examples of how to strengthen medicines commissioning and optimise medicines use in the NHS. Brigitte van der Zanden MSc (Hons) DipClinPharm MRPharmS, SWL Lead Commissioning Pharmacist, South East CSU

11:15 12:15

Integrated Digital Care Fund Case Studies eHospital: an EPIC case study; Big Bang EPMA – did it hurt? Andrew Staples MPharm Hons MPharmres Clin Dip, Lead Pharmacist for Electronic Prescribing / Application Coordinator Medicines management and Pharmacy, Addenbrookes, CUHFT Applying for tech fund money and what happened next…. our ePMA journey Join us in our journey of e-prescribing implementation in a district general hospital. Despair with us at the prolonged gestation, share our joy at successfully navigating the tech fund bidding process and our relief at finally going live on a ward with no catastrophes. Find out how we approached file building and training, the initial roll out to the first ward and subsequent spread. We will share the lessons we learnt along the way, the careful plans that had to be changed and the frustrations we overcame. Laugh at our errors, learn our lessons and go do it yourself. Dipa Pattni MPharm MRPharmS MSc , Electronic Prescribing and Medicines Administration (EPMA) Lead Pharmacist , Luton and Dunstable Hospital NHS Foundation Trust; Damien Kelly MPharm MSc MRPharmS, Site Lead Pharmacist, Royal London Hospital, Barts Health and Mary Evans, Chief Pharmacist, Luton and Dunstable Hospital NHS Foundation Trust

14:00 14:30

The development of pre-reg, junior and senior pharmacist roles in general practice Currently there is a workforce crisis within general practice. The RCGP has stated its fears of an impending GP workforce crisis amid a backdrop of dwindling practice nursing staff and a changing ad increasing population with complex healthcare needs needing to be cared for within the NHS ethos ‘no decision about me, without me’. There appears to be a realisation that in pharmacists, the NHS has workforce more than capable of filling the void. Ravi Sharma MRPharmS, Director of Primary Care Pharmacy, Training and Development, DMC Healthcare and Atif Shamim, Programme Director, CEPN Pharmacy Project and Specialist Programme Support Pharmacist, Health Education Kent Surrey and Sussex

14:45 15:15

Summary Care Records in SCR in hospital and community pharmacy This key session will give a brief history of Summary Care Records and highlight how they are used by pharmacy teams in hospital and community pharmacy. How SCRs benefit patient care, improve efficiency and support safer care? Your chance to get up to speed on this key innovation from a leading expert. Mohammed Hussain MRPharmS, Chair, Pharmacy LPN, West Yorkshire and Independent Pharmacist, NHS England

15:30 16:00

The lighter side of pharmacy What’s the best thing about the NHS? Which medication smells like beer? What if the Fresh Prince was a pharmacist? If the third Die Hard movie had been called ‘Die Hard with a Viagra’, would the plot have been different? We are in the middle of a ‘Great Pharmacy Depression. People need cheering up. This presentation may achieve that. Mr Dispenser MRPharmS, Community Pharmacist and Author, Mr Dispenser

Hospital medication related technology: What’s – Appening? A review of IT developments that link to pharmacy and medicines optimisation including use of “Apps”, analytics, eReferral systems and wearables. What is or could be coming. Andrew Davies MRPharmS, Director of Pharmacy, North Bristol NHS Trust

Biosimilar monoclonal antibodies Biosimilar monoclonal antibodies will start to become available in the UK in early 2015, there are implications regarding their introduction which will be of relevance to clinical, technical and commissioning pharmacists. This presentation will look at the opportunities which these molecules will offer and also the 15:15 potential issues which are likely to arise as they are introduced, and how these may be risk managed. 15:45 Mark Santillo MRPharmS, Regional Quality Assurance Officer, South Devon Healthcare NHS Foundation Trust In association with:

16:15 16:45

Cloud busting - my experience with Pharmapod’s Incident Reporting and Learning System The role of the medicines safety officer and innovative technology that can be deployed to improve patient safety. A showcase of Pharmapod technology and experience of its use in a community pharmacy. Mohammed Hussain MRPharmS, Chair, Pharmacy LPN,WestYorkshire and Independent Pharmacist, NHS England Sponsored by:

17:15 17:45

Patient self-administration of medicines: The journey so far at University Hospitals Bristol University Hospitals Bristol is a large NHS hospital. Opportunity for patients to safely selfadministration their medicines whilst in hospital is supported by a range of organizations, for example CQC and patient groups, for example patients who require subcutaneous insulin. Safe patient selfadministration of their medicines has been reported to have several benefits including; improved patient understanding of their medicines, preparation for discharge, reduced re-admission and reduced medicines wastage. This presentation describes the journey taken to provide safe medicine storage at the bedside, obtaining engagement with staff, measuring success and ongoing improvement work. Helen Ireland MEd MRPharmS, Pharmacist, University Hospitals Bristol

Breakfast symposium: From hospital to home - the focus on the patient* Considerations from the patient perspective, overcoming some common mishaps and learning from experience on managing patients prescribed oral anticoagulation. Nadya Hamedi, ‘DARZI’ Fellow, UCL Partners and Barts Health NHS Trust in collaboration with North Central London Local Pharmaceutical Committee and Lynne Garforth BSc(Hons) PGDip Ipresc, Clinical Primary Care Pharmacist, Ashburton Prescribing Consultants

Association of Pharmacy Technicians UK (APTUK)

The Professional Leadership Body for Pharmacy Technicians What does the future look like for the pharmacy technician profession? As the need is recognised for a greater emphasis on public health and the challenges to an over stretched NHS, the focus is on pharmacy services to become the ‘first point of contact’ for minor ailments and many long term conditions that would traditionally have been or are dealt with by GPs or hospitals. So where do pharmacy technicians fit into this vision? As the professional leadership body for pharmacy technicians APTUK have been representing the profession at a number of events looking at how all the healthcare professions can work as part of a single service to move to a ‘one system’ that is easy to use by patients and that makes the best use of all resources. APTUK suggests and emphasises that pharmacy technicians have a role to play in supporting these services, as professionals who are an integral part of the medicine supplies chain. In addition many pharmacy technicians already work within medicines information and in GP practices and have skills and knowledge that could, with additional training and working as part of a pharmacy team, be transferred across to further help support this agenda. APTUK wholeheartedly support the need for training and personal development for each pharmacy technician, and recognise the need to support trainees, qualified pharmacy technicians and those responsible for training and developing staff. As a result, APTUK have developed the Foundation Pharmacy Framework. This framework is available to all, with additional supporting resources available for our members. More information can be found at www. aptuk.org To realise new ways of working and in supporting innovation to deliver high quality patient centred care, good systems are needed to help teams to get involved in daily improvement and learning. APTUK have been working alongside the RPS and PFNI, to develop an online resources hub that can help pharmacy staff build quality into any new system or way of

Ellen Williams - Events Officer APTUK

working. We urge you to all to have a look at this website, as it’s a valuable resource for us all to use: www.pharmacyQS.com. We are also delighted that this work will be showcased at the congress Another key area that APTUK have been involved in is the work being undertaken by The Rebalancing Medicines Legislation and Pharmacy Regulation Programme Board (RPB) to amend the ‘Pharmacy Order 2010’, so that the standards will no longer be in the rules. This will mean that any failures to meet the pharmacy standards can be dealt with by the GPhC in the same way it would deal with pharmacist and pharmacy technician registrants. The other aspect of the ‘Rebalancing Medicines Legislation and Pharmacy Regulation Programme’ is to provide a defence against section 63 and 64 of the Medicines Act 1968, for registered pharmacy professionals making a single inadvertent dispensing error. You may already have seen on the APTUK website, that a consultation into these proposed changes was launched on the 12th February 15 and is due to close on the 14th May 15. We urge you all to look at the consultation, engage with this important legal change and either give your opinions individually or feedback through one of your local APTUK branch events. We have given the branches information and resources to help with this. APTUK are proud to be a partner of the Clinical Pharmacy Congress and encourage as many pharmacy technicians as possible to take the opportunity to come along, hear about some of the work we have mentioned here, enhance your knowledge through the educational sessions, and network with other pharmacy professionals. APTUK National Officers will be representing the Association at the event and we always enjoy this opportunity to meet members and other pharmacy technicians so please do ensure you come along to your APTUK stand and say hello. We’re looking forward to seeing there.

www.aptuk.org

Tess Fenn - President APTUK

www.pharmacycongress.co.uk

THE LONDON CLINIC KoRa Healthcare specialises in the research, development and marketing of specialist healthcare products in nutrition and genito-urinary medicine. Clinical practice at Harley Street: The Pharmacist “So you are off to work at a private hospital, very posh eh? ...Paracetamol and Tramadol TTOs all the time!” my former colleagues commented. Sometimes, the reality is quite removed from the perceived notions and in fact, working as a Pharmacist at “The London Clinic” (TLC) is ever so challenging. I thank my mentors from the NHS who supported my professional development and nurturing a strong foundation. On a daily basis, I must be a good generalist with confidence and broad knowledge in clinical pharmacy. Yet I also closely work with an experienced multi-disciplinary team looking after complicated patient cases. I recall an overseas patient being admitted via air ambulance after suffering the injuries of machine gun shots. He had subsequently undergone multiple bowel surgeries with stoma, removal of a kidney, part of the liver, spleen, and osteotomy with all of this supported by intense clinical attention. I am challenged by questions such as, “What brand-names of drug ‘A’ are available in Germany?”, and by interesting prescriptions such as oral gentamicin for persistent small intestinal bacterial overgrowth and Targinact TDS for difficult post-op pain relief. At TLC, we strongly believe in evidence based practice and remain flexible in offering a diverse range of treatments to suit patient needs. In 2013, our procurement team sourced Tafamidis from Belgium - a drug which remains restricted in the NHS today, because it costs as much as new VW Polo! As pharmacists, we all understand we must avoid using jargon. Great communication skills are a crucial asset when simple tasks like confirming a patient’s allergy status can become (hasesseeya)’ is a vital word in my confusing, if this patient is fluent only in Arabic. practice. TLC is a unique workplace that challenges me to learn and explore other cultures and maintain a healthy respect for various religious beliefs and patient confidentiality. There is great job satisfaction when patients appreciate my input in their care. This has led me to cultivate a stronger patient-focused Pharmacy service, particularly where balancing wellbeing and cost implications are concerned. Practicing at “Harley Street” may be a status symbol for some but has never gone to my head. I still see myself as a pharmacist with passion and strong focus on quality. TLC brings a wealth of opportunities for me to learn and to grow professionally and personally.

O H3CO

CH3

NEW RESEARCH CH3

Adjunctive therapy reduces all-cause mortality in chronic heart failure (CHF) patients by 43%. H3CO

CH3

Visit us on stand B48 and ask about the Q-Symbio1 trial. T: 01670 519 989 E: specials@pharmanord.com W: www.pharmanord.co.uk

Research papers available on request.

Locum jobs for AHPs

From the UK’s leading medical recruiter ID Medical, the UK’s leading multi-discipline healthcare recruiter holds preferred supplier contracts with over 85% of NHS Trusts nationwide. Our experienced AHP/HSS division services every specialty within Allied Healthcare and can offer you the best pharmacist jobs in the locations and hospitals of your choice...

Visit us at stand E10 Register with us for the latest job opportunities and ﬁnd out why we’re the fastest growing AHP/HSS recruiter in the UK

WWW.ID-MEDICAL.COM Mortensen SA et al. The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure, Journal of the American College of Cardiology, 2014. 1

ClinicalCongress-Mar15.indd 1

17/03/2015 11:07:22

T: 01908 552 283 E: ahp@id-medical.com /IDMedical uk.linkedin.com/in/idmedicalahp

www.pharmacycongress.co.uk

Industry-led Symposia FRIDAY 24TH APRIL 09:00 - 09:45 Keynote Theatre A brief history of time – past, present and future of anticoagulation* This session will provide an overview of the developments of anticoagulation from original ‘blood thinners’ through to unfractionated heparin, warfarin, LMWH through to the more recent developments of NOACs, touching on the development of future indications. Learning outcomes: 1. To be able to outline the key developments within anticoagulation. 2. To list the pit falls of ‘older’ anticoagulation that has led to the continued development of anticoagulants and identify the key criteria for the ‘ideal anticoagulant’ 3. To explore potential opportunities for anticoagulation for future indications Sotiris Antoniou FFRPS MRPharmS MSc Dip Mgt Ipresc, Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust and Daniel Buck MPharm DipClinPharm Ipresc, Specialist Pharmacist – Anticoagulation, Wrightington, Wigan and Leigh NHS Foundation Trust

09:00 - 09:45 Clinical Theatre 1 Relapse prevention in schizophrenia and the role of the multidisciplinary treatment team* • Relapse prevention and reduced hospitalisation as the primary goal of the treatment team • Acknowledged lack of patient insight in psychosis • The need for positive and coordinated care • Awareness and discussion of available treatment options and the importance of treatment individualisation for improved therapeutic alliance and patient quality of life Learning outcomes: 1. Pharmacists have a valuable role to play as part of the multidisciplinary team in treating people with psychosis 2. Preventing relapse and hospitalisation are key treatment goals in managing patients with schizophrenia 3. Collaborative decision-making to individualise treatment is important for maintenance treatment and helps to improve outcomes for patients. Jayaprakash Makala, Consultant Psychiatrist, North Staffordshire NHS Trust

09:00 - 09:45 Clinical Theatre 2

13:00 - 13:45 Clinical Theatre 1

09:00 - 09:45 Leadership Theatre Has the classification of drugs for pain been overtaken by successive developments such as Palexia and novel targets?* We present the case and a solution for a new mechanism-based system. Learning outcomes: 1. Overview of current classification of pain medicines and their inadequacies 2. Greater understanding of the mechanisms of pain and clinical implications for treatment 3. The importance of mechanism of action of medicines when deciding on appropriate treatment for pain • Medicinal chemistry of current treatments Professor Richard Langford, MB;BS FRCA FFPMRCA, Founder/ Director of Pain and Anaesthesia Research Centre and Paul Farquhar-Smith, Consultant in Pain and Anaesthetics and Fellow of the Faculty of Pain of the Royal College of Anaesthetists and Professor Anthony Dickenson, BSc PhD FmedSci FBPharmcolS, Professor of Neuropharmacology in the Department of Neuroscience, Physiology and Pharmacology, University College, London

12:45 - 13:30 Keynote Theatre Inertia in diabetes: the role of the Specialist Pharmacist and how will this be supported by the NHS 5 Year Plan* Inertia in diabetes is a major issue: Specialised services need to move into Pharmacist care but the core of the debate will be around where should these services sit? How do we build this service? Learning outcomes: The purpose of this symposium is to engage the audiences all who work as Pharmacists to: • Understand the effect of Clinical Inertia for a Diabetic Patient • Explore with the panel the thought that by developing Specialist Pharmacist this might bridge a gap created in the new NHS and as part of a Multi-disciplinary team be a solution to addressing Clinical Inertia.. • We want to raise awareness of the Disease, and for the Diabetic Patient to be in the centre of the debate. Professor Cliff Bailey PhD FRCP(Edin) FRCPathLife and Health Sciences, Professor of Clinical Science and Director of Biomedical Sciences Research, Aston University in Birmingham Phillip Newland –Jones, Advanced Specialist Pharmacist Practitioner in Diabetes, Alison Tennant, CD Accountable Officer, Quality and Safety Pharmacy Services Clinical Lead, NHS England

12:45 - 13:30 Clinical Theatre 2 Oncology Delivered by Roche Details to follow online

12:45 - 13:30 Medicines Optimisation Workshops Health economics and diabetes: the pound vs. the patient* The aim of this training is to equip healthcare professionals with an understanding of the clinical and economic value of treating diabetes from both patient and provider perspectives. Focus will be on ‘drivers’ of value in the allocation of scarce healthcare resources within the NHS based on principles of evidence-based medicine, efficiency and fairness. Learning outcomes: Delegates will gain an improved understanding of: 1. Health Economic approaches to measuring quality of life 2. Effect of diabetes on society – its impact on life and work 3. Methodological aspects of diabetes modelling 4. Modelling diabetes disease progression and its complications 5. Quantifying the cost of diabetes and its complications 6. Application of health economics from population to patient Professor Phil McEwan PhD, Professor & Technical Director, Centre for Health Economics, Swansea University

Translating clinical evidence to experience – cardiology* The session will be delivered through a range of interactive, patient centred scenarios focussing on the evidence from clinical trials in cardiology to improve patient outcomes. A range of aspects will be covered including atrial fibrillation and acute coronary syndromes highlighting key challenges in delivering effective anticoagulation. Learning outcomes: 1. To be able to outline the key trials involving the NOACs in the management of cardiovascular disease. 2. Be able to outline the application of clinical trials into every day practice 3. To explore potential opportunities for pharmacists within the field of cardiovascular Sotiris Antoniou, FFRPS MRPharmS MSc Dip Mgt Ipresc, Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust and Helen Williams, MRPharmS PGDip(Cardiol) Ipresc, Consultant Pharmacist for Cardiovascular Disease for South London, Hosted by Southwark CCG

* This Congress is supported by educational grants from various companies who have not influenced the meeting content or the choice of speakers however those sessions marked with an asterisk (*) are being delivered with input from the sponsoring company.

In pursuit of excellence in the prevention of AF-related stroke What is the true price of AF-related stroke?* Trudie Lobban, Chief Executive of the Atrial Fibrillation Association considers the devastating impact on patients and carers of AF-related stroke. She also discusses the barriers that exist to identification, diagnosis and effective anticoagulation and asks where we are one year on from NICE guidance in AF. What can Pharmacists do to improve patient care? Paul Wright, Lead Cardiac Pharmacist, The Heart Hospital, then examines the role of pharmacy in optimal AF patient care – considering both the importance of medication choice to meet differing patient needs and best practice examples to illustrate how pharmacy is working to improve outcomes in AF. Trudie Lobban, Chief Executive, Atrial Fibrillation Association and Paul Wright, Lead Cardiac Pharmacist, The Heart Hospital

13:00 - 13:45 Leadership Theatre Pharmacy: pivotal in tackling the emerging trend of opioid analgesic dependency* The level of opioid prescribing has increased over the last 10 years, and there is now a small minority of increasing patient numbers reporting to substance misuse services that have become unintentionally addicted to their opioid painkillers. Pharmacists are well placed to recognise patients who have unintentionally developed addiction to opioid analgesics from POM or OTC medication. This presentation will cover: • What is OAD • How patients become dependent • The current trend for OAD • The role of pharmacy (from prevention, identification, screening to treatment) • My role/experience in OAD • Benefit of pharmacy in helping to tackle OAD Duncan Hill MRPharmS, Specialist Pharmacist in Substance Misuse, NHS Lanarkshire

13:00 - 13:45 Strategy and Policy Forum Moving homecare forward – funding models, partnership working, quality and safety * Bupa Home Healthcare’s pharmacy customers were asked what topics are at the forefront of their minds when thinking about home healthcare overall. Three strong themes came through which will be explored in greater detail during the session: Homecare funding models – what are the options for homecare? Partnership working – how can the NHS, home healthcare providers and the pharmaceutical industry best collaborate and work together? Quality and safety – how are providers working towards safer homecare provision? Join us on Friday 24 April, in the Strategy and Policy Forum from 1.00pm -1:45pm to hear our views on the topics, share your thoughts and collectively discuss issues in home healthcare. Lunch will be provided. Stephen Cook, Director of Pharmacy and Quality, Bupa Home Healthcare

14.15- 15:00 Clinical Theatre 2 Insight into Actinic Keratosis Management in Primary Care and potential medicines optimisation opportunities* Insight into the management of actinic keratosis in primary care in the Greater Manchester area Due to the wide variation in AK presentations, the range of therapies available, high rates of recurrence and feedback from patients seen in the specialist referral centre, there is a need to gain a deeper understanding of the patient journey from symptoms, through diagnosis and treatment, to outcomes. The project focus was on patients who received topical treatment for AK within the last 5 years, as some of these patients would be amongst the least likely to be referred for specialist AK treatment. The presentation will examine the results of this retrospective audit. Learning outcomes:

= Hot drink and pastry will be provided

= Lunch bag will be provided

www.pharmacycongress.co.uk

1. The majority of patients are being diagnosed and managed within the primary care setting, in-line with guidance. 2. However, a coherent approach to lesion classification was rarely seen to be recorded, therefore, making it difficult to assess whether the best possible treatment(s) was being prescribed. 3. An important finding arising from this audit showed that following 61% of treatments prescribed for AK, patients had no record of a follow-up assessment 4. The findings from the audit identified a need to improve follow-up rates in patients. Dr John Lear, Consultant Dermatologist, Manchester Royal Infirmary Medicines optimisation opportunities in actinic keratosis The management of actinic keratosis presents several opportunities to focus on medicines optimisation to improve outcomes and reduce harms to patients. This presentation will explore some of the common issues raised with the medicines optimisation team. Learning outcomes: 1. Patients that can be managed appropriately in primary care 2. Opportunities for medicines optimisation in AK 3. Opportunities for patient’s education and increased concordance. Claire Vaughan, Head of Medicines Management, Salford CCG

15:30 - 16:15 Medicines Optimisation Workshops Responsible respiratory prescribing* Responsible Respiratory Prescribing is “Doing the Right Thing and Doing the Right Things Right”. We will debate the background behind the “guidelines”, reveal the truth that is value based healthcare in respiratory medicine and shock you with how far from this we really are. If you look after anyone with a lung disease, or you have ever added the prefix “only-” or “just-” to asthma or COPD, this session is for you... Grainne d’Ancona, GPhC MSc MClinRes IPrescr MFRPSII, Principal Pharmacist (acute medicine) and Clinical Lecturer, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London and Dr Vince Mak, Consultant Physician in Respiratory Integrated Care, Imperial College Healthcare and Central London Community Healthcare NHS Trusts

SATURDAY 25TH APRIL 09:00 - 09:45 Clinical Theatre 2 Tackling the barriers to diabetes management* A session exploring the challenges of clinical inertia and poor concordance in patients with type 2 diabetes with an extended discussion on resources, tools and pharmacotherapy to support the health care professional. Learning outcomes: • Why is clinical inertia and concordance important in the management of patients with type 2 diabetes. • Understand the role of Forxiga (dapagliflozin) and Bydureon (Exenatide once weekly) in the management of type 2 diabetes. • Gain practical advice on the management of clinical inertia and concordance in daily practice. Learning outcomes: 1. Why is clinical inertia and concordance important in the management of patients with type 2 diabetes 2. Understand the role of Forxiga (dapagliflozin) and Bydureon (Exenatide once weekly) in the management of type 2 diabetes. 3. Gain practical advice on the management of clinical inertia and concordance in daily practice. Alia Gilani, Health Inequalities Pharmacist, NHS Glasgow and Dr David McGrane, Consultant Physician, Southern General Hospital in Glasgow

09:00 - 09:45 Innovation & Technology Forum From hospital to home - the focus on the patient* Considerations from the patient perspective, overcoming some common mishaps and learning from experience on managing patients prescribed oral anticoagulation. Learning outcomes: 1. To understand the key risks associated with the transfer of patients from hospital back to the care of their GP and how these risks can be reduced. 2. How to empower your patients to take their anticoagulants and gain maximum benefit from their treatment. 3. Role of pharmacist in supporting patients’ adherence to oral anticoagulants and how this can be embedded in patients care pathway.

Nadya Hamedi, ‘DARZI’ Fellow, UCLPartners and Barts Health NHS Trust in collaboration with North Central London Local Pharmaceutical Committee and Lynne Garforth, Clinical Primary Care Pharmacist, Ashburton Prescribing Consultants

12:45 - 13:30 Keynote Theatre Translating clinical evidence to experience in VTE * The session will be delivered through a range of interactive, patient focussed scenarios focussing on the evidence from clinical trials in VTE to improve patient outcomes. A range of aspects will be covered including VTE services, commissioned activity and VTE management in primary care including transfer of care and management of PE. Learning outcomes: 1. To be able to outline the key VTE trials involving the NOACs. 2. To identify potential treatment options for patients 3. To explore potential opportunities for pharmacists within the field of VTE prevention and treatment 4. To describe potential savings that could be released. Sharron Gordon, Consultant Pharmacist Anticoagulation - Haemophilia Network, Hampshire Hospitals NHS Trust and Barbara Clark, Lead Clinical Pharmacist, London Bridge Hospital

12:45 – 13:30 Leadership Theatre Lipid modification: past, present and future developments* The session will provide an overview of developments in the management of lipids. Describing the role that rabbits played in ‘lipid hypothesis’; to the development of cholesterol lowering agents and beyond statins touching on future developments of managing cholesterol. Learning outcomes: 1. To outline the importance of cholesterol and vascular damage 2. To outline key trials in lipid modification in the management of cardiovascular disease. 3. Understand that statins may not be the sole solution to lipid modification 4. Be able to outline the application of clinical trials into every day practice 5. To explore potential opportunities for pharmacists within the field of cardiovascular Sotiris Antoniou FFRPS MRPharmS MSc Dip Mgt IPresc, Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust

13:00 - 13:45 Clinical Theatre 1 Lunch symposium: Improving treatment outcomes in type 2 diabetes: SGLT2 inhibitors and INVOKANA* Details to follow online. Delivered by Janssen

13:00 - 13:45 Clinical Theatre 2 Access to medicines in rheumatology: assessing and presenting the evidence* This symposium will seek to assist pharmacists in product formulary submissions, ensuring patients have access to the most appropriate treatments in line with evidence-based medicine and personalised care. Dr Anthony Grosso will first offer practical advice on how to be successful in submitting formulary applications for Payment by Results (PbR) excluded drugs. Dr Andrew Östör will then provide an overview and assessment of the clinical evidence for the use of biologic monotherapies in RA, incorporating personal clinical experiences throughout. The mode of action of different biologics will be discussed, suggesting why differences in treatment response can be seen. Learning outcomes: 1. How to build the most comprehensive case to take to the Drugs and Therapeutic Committee 2. Understanding the clinical evidence surrounding biologic monotherapies in rheumatoid arthritis 3. Appreciation of the mode of action of different biologics and how this can impact on response Dr Anthony Grosso, Principal Pharmacist, University College London Hospital and Dr Andrew Östör, Consultant Rheumatologist, Addenbrooke’s Hospital

Don’t forget! Laerdal Simulation Zone Friday 24th

09:00, 11:00, 14:00, 15:00, 16:00, 17:30

Saturday 25th

09:15, 10:15, 11:15, 12:15, 14:00, 15:00

Half hour sessions with a small group of delegates will allow you to see Laerdal SimMan 3G, a realistic, full-body adult, wireless patient simulator close up. Sessions must be booked in advance.

Innovation of the Year Award Friday 24th

09:45

Make sure you visit the Innovation & Technology Forum on Friday to hear from our four shortlisted candidates as they look to impress the judges and take home our award.

Best of Clinical Pharmacy Awards Friday 24th

11:30- 12:30

Following the Keynote address by Dr Bruce Warner, we will unveil the winners of The Best of Clinical Pharmacy Awards for 2015.

Poster Zone Friday 24th 09:30-11:00, 14:30-16:00 Saturday 25th 09:45-11:15, 14:00-15:30 Showcasing work from teams around the UK. Learn best practice from frontrunners in the clinical pharmacy profession. Sponsored by:

Networking Drinks Friday 24th

18:15-19:30

The Congress once again will host a FREE networking drinks reception providing the perfect opportunity to continue networking with your pharmacy colleagues after a busy day!

www.pharmacycongress.co.uk

Controlled Drug and Medication Storage Specialists Since 1963 “New” Electronic Access Control System

D N A ST 2 E5 Controlled Drug Cabinets designed to exceed the Misuse of Drugs (safe custody) Regulations 1973 Medication Cabinets/Storage Systems manufactured to BS2881 the Storage of Medicines in Healthcare Premises and BS3621.

CPC 2015 ARX_Pre Congress Newspaper:Layout 1

18/03/2015

15:16

Page 1

Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ

Secure and Cost Effective Compatible with existing euro profile locks Keys cannot be copied No costly lock replacements in the event of lost keys each key has unique electronic ID Assign beginning/expiration date along with time periods Completely bespoke access privileges for users (which key opens which lock and when) Each key can open from 1 to 3000 locks Audit trail stored in lock and keys Ability to Blacklist lost/stolen keys

Denward Manufacturing Ltd 50 Writtle Road, Chelmsford, Essex, CM1 3BU tel: 01245 492986 email: sales@denward.com

Are you under budgetary pressure? With over 70% of NHS Acute Trusts using an ARX system, ARX has grown to be the market leader in pharmacy automation in the UK. If you need to reduce spend, free up staff time, or improve security, ARX can design and provide the perfect solution to improve your workflow, compliance and reduce stock holding and wastage. ARX can provide a Global Solution, with all of our products working together to create a unique workflow. For example Pyxis® cabinets can automatically request stock, which can be automatically picked by a RowaTM robot. Items can even be loaded into the Pharmaself24 for collection by staff or patients. Come and visit us on Stand E50 to see our systems in action, and to speak to a member of our team.

www.arx-ltd.co.uk

Tel: +44 (0) 1727 893360

Fax: +44 (0) 1727 893361

sales@arx-ltd.co.uk

www.pharmacycongress.co.uk

EXHIBITOR PROFILES Distinctive Medical are the number one supplier of unique and often hard to source items. Our range includes trolleys, high density storage, pharmacy items, security and tamper evident items. At CPC 2015 we will be showcasing our wide range of pharmacy related products, as well as introducing our new product range from ITW Envopak. Our Sales Team will be on hand to discuss the transition between ITW and Distinctive, and to advise you about new and innovative products we are bringing through to the market in the next few months

VISIT US ON STAND D45 Bridging the world of IT and healthcare Promatica is a leading healthcare IT company which combines real health expertise with in-depth IT and business knowledge. We provide the perfect blend of skills and software products to help healthcare organisations improve quality and safety for their patients whilst the same time increasing efficiency and efficacy of their service, leading to “better value” services.

Rosemont Pharmaceuticals Limited is dedicated to improving the health and wellbeing of people through the development, manufacturing and marketing of high quality generic oral liquid medicines. We are leading specialists in the supply of liquid medicines for people who have swallowing difficulties, or for those who need a precise measured dose unavailable in a solid tablet or capsule. Through significant research and development, we manufacture a range of more than 160 different liquid formulations covering 10 BNF categories. Acquired by Perrigo Company plc in 2013, we have 46 years experience in supplying both licensed and ‘Specials’ oral liquid medicines to customers who see Rosemont as ‘The Source of Liquid Solutions’. Rosemont’s commitment is to the promotion of best practice when administering medication; through continuing support of healthcare professionals and the provision of free educational training meetings and materials to assist them in delivering the best possible care for their patients.

VISIT US ON STAND H19

For further information please see our company website www.promatica.co.uk

TLTP Medical is a framework agency and a market leader in the Pharmacy Department Sector. We are a premier supplier of locum and permanent staff to the Allied Health Professionals and Health Science Services. TLTP Medical is London-based and deploys Pharmacists and Pharmacy Technicians throughout the UK and Overseas. We strive to pair the best candidates and clients to achieve a perfect working relationship. Our team work vigorously to ensure that our candidates find their perfect role. TLTP Medical prides us on our aftercare and support for our candidates, by maintaining regular contact with them to ensure they are always happy. We keep in constant contact with our clients to understand their needs and we find them the best possible candidates that are fully compliant. TLTP Medical does not charge premium rates although it does delivery a premium service. We strive to provide the finest service in the medical sector.

VISIT US ON STAND D42

VISIT US ON STAND G30

Software Products - We offer a range of award winning software products, each of which have been proven to provide significant and measurable benefits: Medcura – IV®, Medcura – PX®, Knowledge Manager QMS, Web Tracker, Clinical Trial Manager, EPMA Analytics and Xtag Consultancy - As the implementation of IT healthcare systems gathers pace across the world, evidence has shown that these systems in themselves pose significant safety risks. ISB standards 129 and 160 are there to support the mitigation of these risks through a robust and systematic risk management process. Promatica’s team of clinical safety officers and safety engineers have an excellent track record of taking IT companies and the NHS through ISB 0129 certification. We can also help healthcare organisations to go through their corresponding ISB0160 certification. Our team of professionals are recognised as unique, safety-centred ISB standard providers. We use a strong and sustainable approach to patient safety, staff education and improvement both within the NHS and business services.

Beta them!

R 3 YEA ti o n

The NEW, revolutionary, non-corrosive sporicide

iBin Innovations specialise in the safe handling of medicines, from the Pharmacy to the wards. The products we provide help to generate best working practices, creating time saving efficiencies whilst enhancing the security and control of medicines. We pride ourselves on being able to look at the dayto-day issues our customers face and identify bespoke solutions to overcome them. Using our range of products and working practices our customers have seen a 30% increase in Medicines Reconciliation within 24 hours of admission, 100% of TTOs are now completed within the target time, (an increase of 75%). Turnaround time for urgent TTOs has dropped from 125 minutes to 32 minutes. Our products include our flagship MediBin, Returns MediBin, tamper evident Pharmacy pouches and bags, arrow and button seals and a full range of tamper evident security ties. Please visit our website at www. ibinmedical.com

VISIT US ON STAND G9

Written Medicine is an award winning start-up that have created a web-based software, which can translate and print bilingual pharmacy dispensing labels for ethnic minority patients that may have a limited ability in English. The co-founders created the software after experiencing communication barriers with patients in pharmacies they work in. According to the 2011 Census, 5 million people in the UK speak English as a second language, of which 1 million speak English poorly or not at all. These numbers do not include the 900,000 undocumented migrants, 250,000 international students and 6 million approximate foreign workers. Bilingual dispensing labels will reduce the communication barrier between the pharmacist and the limited English speaking patient, providing crucial information about their medication, which is one of the GPhC standards. The software is currently available in 5 languages; Arabic, Bengali, Polish, Punjabi/Gurmukhi and Somali With another 7 languages coming soon.

VISIT US ON STAND G59

FREE

If you don’t want to join them

C a li b ra S e rv ic e

an d War ra n ty

FREE

A 3sure sign R A E Y it’s Shoreline C a li b ra ti o n S e rv ic e an d War ra n ty

Medical refrigeration designed and built with expertise and care

Non-Corrosive Independently tested and approved

Shoreline is the only UK medical refrigerator

Anti-tamper fitting

manufacturer to support it`s products with a free 3 year

No leaks, no re-use possible

warranty and free 3 year annual calibration service.

Ergonomic design

That`s because we understand healthcare professionals`

User comfort and protection

needs, above all else, for assurance of reliability

Alpha and Beta are available in 500ml Trigger Sprays, Wipes, Mops, 5 Litre containers and Single Dose.

and product performance. With lots of great features, our products focus on

Encapsulated irradiation indicator No paper, no ink present

key areas like temperature control, temperature

Transparent bottle

monitoring and energy efficiency, but also deliver

Contents visually obvious

ease of use, product security, auto-defrosting and. of course, great value.

For information, technical support, prices and availability

There’s a Beta solution for all your cleanroom needs

Quality Innovative Solutions

Roman Bank, Skegness, Lincs., PE25 1SQ Tel: 01754 767377 Fax: 0845 2992166 Email: enquiries@micronclean.co.uk

Call us on 01903 733 877

or email ask@shoreline-medical.co.uk www.shoreline-medical.co.uk

Web: www.micronclean.co.uk Web: www.micronclean.eu Garments & Mops website Consumables website ISO 9001

ISO 14001

ISO 13485

EN 14065

s m ou r a as ia.co e y fo n P ed Ar ible tio stillm ig ca ser el u clo Ed tel@ ee .pa fr ail: m em

The Home of Clinical Pharmacy Whatever your role in clinical pharmacy… we have it covered:  You can expect a faculty of over 100 world-class speakers, programmed by the Centre for Pharmacy Postgraduate Education (CPPE) and the Royal Pharmaceutical Society (RPS)

 N etwork with 2,000 colleagues, peers and friends in the UK’s largest industry gathering

 73 hours of cutting-edge clinical content for your personal CPD  New medicines and specialist pharmacy technology and equipment suppliers to learn from (over 130)  Celebrate the Best of Clinical Pharmacy Award winners

Leadership partner:

Accredited by:

CIETY SO

ROYAL P H

EU MAC TICA AR

Accredited by:

Conference partners:

Leadership partner:

E DIT E D

5 201

Strategy and Policy Forum sponsor: PE

Charity partner:

Education partners:

UK Renal Pharmacy Group

EU MAC TICA AR

CIETY SO

 Hands-on training with the Laerdal Simulation Zone

Lead education partner:

 Access updates in the NEW Strategy and Policy Forum

ROYAL P H

 Share best practice in NEW Poster Zone

1 E DIT E D 20